ANNUAL REPORT 2022
# TABLE OF CONTENTS

1. INTRODUCTION .......................................................................................................................... 2

2. ABOUT THE EUROPEAN HEMATOLOGY ASSOCIATION .............................................................. 3

3. SUPPORTING CAREER DEVELOPMENT AND RESEARCH .......................................................... 8

4. ADVOCATING FOR A BETTER FUTURE .......................................................................................... 10

5. CONNECTING HEMATOLOGISTS WORLDWIDE .......................................................................... 13

6. HARMONIZING AND BUILDING KNOWLEDGE ......................................................................... 15

7. LOOKING FORWARD TO 2023 .................................................................................................... 17

8. APPENDIX .................................................................................................................................. 19

## 8.1 SUPPORTING CAREER DEVELOPMENT AND RESEARCH

- EHA RESEARCH COMMITTEE ........................................................................................................ 23
- EHA GUIDELINES .......................................................................................................................... 24
- HEMASPHERE ............................................................................................................................... 27
- EHA GRANTS 2022 ......................................................................................................................... 30
- TALENT ACCELERATOR MENTORING PROGRAMS .................................................................... 38

## 8.2 ADVOCATING FOR A BETTER FUTURE

- HARMONY ALLIANCE .................................................................................................................... 45

## 8.3 CONNECTING HEMATOLOGISTS WORLDWIDE

- EHA SCIENTIFIC WORKING GROUPS AND MEETINGS .............................................................. 51
- EHA AND NATIONAL SOCIETIES .................................................................................................. 57
- 2022 ACTIVITIES YOUNG HA COMMITTEE ................................................................................. 59
- ANNUAL CONGRESS EHA2022 HYBRID CONGRESS .................................................................. 62

## 8.4 HARMONIZING AND BUILDING KNOWLEDGE

- HIGHLIGHTS OF PAST EHA (HOPE) ............................................................................................ 82
- EUROPEAN PROJECTS ABOUT CELLULAR THERAPIES: T2EVOLVE ...................................... 88
- EUROPEAN PROJECTS ABOUT CELLULAR THERAPIES: GOCART ....................................... 89

9. FINANCIAL REPORT .................................................................................................................... 91
This Annual Report contains an overview of EHA’s activities in 2022, executed to support EHA’s mission:

“The European Hematology Association (EHA) promotes excellence in patient care, research, and education in hematology.”
INTRODUCTION

“EHA IN 2022: OVERCOMING UNCERTAINTY TOGETHER”

International conflicts, economic and geopolitical upheavals and the tail of the pandemic dominated 2022. It was a year of uncertainty for everyone, including the hematology community. This annual report describes how the European Hematology Association (EHA) continued working together to maintain our objectives and achieve our goals throughout this 30th anniversary year.

Committed to an Inspiring Vision, Together

The European Hematology Association is committed to connecting hematologists worldwide, and we were delighted by the strong interest in the 2022 EHA Congress in Vienna, hosting 17,000 registrants from 122 countries. It was a wonderful opportunity to reunite the hematological community in person after two years of virtual congresses. We also look back at a vibrant first edition of the EHA Research Conference in Italy as well as our recurring Specialized Working Group (SWG) meetings, national societies engagements and worldwide Hematology Tutorials. The commitment of our members and associates is truly inspiring.

Part of EHA’s mission is to support career development, clinical practice and research. Due to the international conflicts this was more salient than ever. EHA launched several opportunities to support Ukrainian hematologists, patients in need, lack of medical supplies, and most recently, the Ukraine Bridge Funding program to help hematology researchers in exile, in preparation for their future return home. In keeping with our community vision, EHA continues to strengthen its solidarity, now with Ukraine.

Raising the Voice of the Hematologist Community

The global health, economic, and political events of the past year have emphasized how vital it is to ensure that the voice of hematologists and the entire hematology community continues to be heard. EHA has worked continuously to influence and contribute to the development of the emerging EU health policy, revision of EU legislation and funding programs in hematology-related topics, e.g. fair pricing of innovative medicines, precision diagnostics, personalized medicine and development of European-level health technology assessment.

Harmonizing the Hematology Knowledge

EHA also reinforced its passion to harmonize hematology education with the release of new clinical practice guidelines for malignant hematology and exciting educational off/on-line programs on the EHA Campus, microlearning on social media and podcasts). Highlighting a memorable year for HemaSphere, EHA’s official journal, received its first impact factor of 8.3, reflecting the quality of submissions and the excellent editorial team.
An expanded office

Our ever-increasing activities required significant adaptation to the office team, onboarding an increasing range of specialized, internationally representative, professionals. We also recently welcomed our new Managing Director, Ignacio Quiles, who has brought his expertise from the research, management and industrial spheres, in addition to some Iberian sunshine! We wish him all success in his career at EHA!

You can find the summary of our various initiatives below.

Overall, the range and positive reception of our activities across the board demonstrate clearly how well we pulled together in this tough year, objective proof of our unwavering commitment to advancing the field of hematology in Europe and beyond. As I near the end of my two-year presidency, I am confident that we will continue to do even more in years to come.

Prof Elizabeth Macintyre
EHA President
Since 1992, EHA is a membership organization serving healthcare professionals with an active interest in hematology. Together with researchers, clinicians, patient support groups, other key stakeholders and more than 5,000 members from Europe and beyond, EHA works towards a cure for all blood disorders.

We are proud to be the largest Europe-based organization connecting hematologists. In doing so, we stick to our core values of independence, integrity, and transparency. This in turn is underpinned by our mission statement of: “EHA promotes excellence in patient care, research, and education in hematology”.
GOVERNANCE STRUCTURE

EHA IS OVERSEEN BY A BOARD OF 16 ELECTED MEMBERS, WHICH SETS GOALS AND OBJECTIVES IN CONFORMITY WITH THE STATUTES AND ESTABLISHES COMMITTEES AND UNITS TO GUIDE AND PERFORM SPECIFIC TASKS AND ACTIVITIES. THE BOARD, COMMITTEES AND UNITS ARE SUPPORTED BY THE EXECUTIVE OFFICE.

THE 2022 EXECUTIVE BOARD CONSISTS OF:

- Elizabeth Macintyre, President
- Konstanze Döhner, Treasurer
- John Gribben, Past President
- Kirsten Grønbæk, Secretary
- Antonio Almeida, President-elect
- Martin Dreyling, General Member

THE 2022 BOARD COUNCILORS ARE:
MERITXELL ALBERICH, MARIA CHIARA BONINI, JEAN-PIERRE BOURQUIN, RAÚL CÓRDOBA, HERMANN EINSELE, BRIAN HUNTLY, FRANK LEEBEEK, MARIANE DE MONTALEMBERT, CAROL MORENO, JOSÉ MARIA RIBERA
The 21 currently active EHA committees involve 190 members (with some overlap) from 30 countries and include:

- Curriculum-Exam Committee
- EHA Campus Working Group
- European Board for Accreditation in Hematology
- Education Committee
- EHA-ASH TRTH Joint Oversight Committee
- European Affairs Committee
- Fellowships and Grants Committee
- Global Outreach Program Committee
- Good Governance Committee
- Guidelines Committee
- HemaSphere Editorial Board
- Membership & Community Engagement Committee
- Nomination Committee
- Online Case Unit
- Patient Advocacy Committee
- Research Committee
- Scientific Program Committee, EHA Congress 2023
- SPC Advisory Board, EHA Congress 2023
- Sponsor and Fundraising Committee
- SWG Committee
- YoungEHA Committee

The EHA Board and its committees are supported by the Executive Office, located in The Hague, the Netherlands. An international team of staff works in a dynamic, collaborative, and open environment, taking pride in serving the hematology community in Europe and beyond.
A snapshot of EHA's 2022 activities can be grouped into four pillars.

**EHA Activities**

- **Connecting**: Hematologists worldwide
- **Supporting**: Career development and research
- **Advocating**: For a better future
- **Harmonizing**: And building knowledge

‘Together, we are the architects of hematology.’
SUPPORTING CAREER DEVELOPMENT AND RESEARCH

EHA enables European hematologists to play leading roles in developing curative approaches for patients with hematologic diseases. It does so by fostering knowledge across the entire field of hematology through its Specialized Working Groups (SWGs) and by supporting the careers of promising scientists through grants and mentoring.

Return to in-person mentoring programs

EHA mentoring programs are a unique opportunity to engage with peers and faculty through learning beyond the formal classroom. After a two-year break due to the pandemic, in-person mentoring programs were re-started in 2022. These included:

Supporting careers through grants

EHA accelerates the careers of promising hematology researchers by providing EHA Research Grants, funding lab-based research of talented early career researchers and physician-scientists. In 2022, the following grants were awarded:

In 2022, the following grants were awarded:

- Two Junior Research Grants: EUR 50,000 per year, for three years
- Three Advanced Research Grants: EUR 80,000 per year, for two years
- One Physician Scientists’ Research Grant: EUR 80,000 per year, for two years
- One Topic-in-Focus Junior Research Grant: EUR 50,000 per year, for three years
- One Topic-in-Focus Advanced Research Grant: EUR 80,000 per year, for two years
- Six Kick-off Grants: EUR 50,000, for one year
- Two Bilateral Collaborative Grants
- Eleven Research Mobility Grants

The Clinical Research Training in Hematology (CRTH), a nine-month unique training and mentoring experience focused on clinical research in Europe for 20 early-career researchers.

The EHA-ASH Translational Research Training in Hematology (TRTH), a joint effort of EHA and the American Society of Hematology (ASH) focused on helping early-career hematological scientists build successful careers in translational research with an increase from 20 to 24 beneficiaries for the "class of '23".

The new Computational Biology Training in Hematology (CBTH) is a collaboration between the European Hematology Association and the European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI) that aims to equip hematology researchers with essential computational biology skills. The call for this program opened in 2022.

EHA gave out 27 grants in 2022.
Harmonization with Specialized Working Groups

EHA partners with SWGs to foster science and spread knowledge in basic, translational and clinical research and practice in hematology in Europe. A total of 24 groups are closely involved in European affairs with special initiatives such as EuNet-INNOCRION (European Network for Innovative Diagnosis and Treatment of Chronic Neutropenias) and the new EHA Taskforce for Adolescents and Young Adults with Hematologic Diseases.

This year, we developed a new SWG framework to harmonize and facilitate the efforts of the EHA and SWGs. We also established grants to support small, SWG-initiated seed-funding type research, with three winners selected at the end of 2022:

- SWG on AML: “Evaluation of the prognostic impact of subclonal FLT3-ITD mutations in acute myeloid leukemia: a retrospective multicenter study on behalf of the EHA AML-SWG” - Professor Maria Teresa Voso and Dr. Carmelo Gurnari
- SWG on Precision Hematology: “Standards for Functional Precision Medicine (StFPM)” - Professor Philipp Staber
- SWG Lymphoma Group "Long-term outcomes in patients with SMZL treated in the Rituximab Era” - Dr. Ahmed Ludvigsen Al-Mashhadi

Since I’ve been a member, I have to say that [...] I’ve increasingly been involved in EHA and realizing the potential that EHA has.

- Alba Maiques-Diaz, YoungEHA Committee Member
ADVOCATING FOR A BETTER FUTURE

EHA is the face and voice of hematology and hematology professionals in Europe, raising awareness of hematology as a distinct medical discipline with specific needs and promoting the interests of EHA members in key policy areas.

EHA engages with EU institutions and with a variety of stakeholders, constructively and consistently, to advance the interests of its members. Amid a broad range of actions deployed in support of our main advocacy goals – affordable and equitable access to innovative therapies, more support for hematology research, and an improved regulatory framework – the following stood out in 2022:

**Health Data Strategy:** Adoption of an EHA Health Data Strategy and strong involvement in discussions on the emerging European Health Data Space. An effective and harmonized European framework for data collection and data sharing is crucial for the work of researchers, clinicians and diagnosticians in hematology.

**Collaboration with European Medicines Agency (EMA):** There were two new milestones in the collaboration with the EMA. A joint workshop for EHA and EMA leadership and the inclusion of EHA in the new Cancer Medicines Forum, where regulators and academia discuss post-authorization optimization of cancer treatments, testified to the increasing prominence and strength of EHA’s regulatory relations at EU level.

**Focus on Adolescents and Young Adults (AYA):** Marking another step in connecting EHA’s scientific and medical community with the EU policy and regulatory environment, we created a taskforce for AYA. Its aim is to develop a coherent EHA approach on AYA care in hematology, identify gaps and challenges, and inform targeted advocacy actions.

**Reducing Bureaucracy in Clinical Trials:** To promote awareness and uptake of the Recommendations of the Coalition for Reducing Bureaucracy in Clinical Trials (‘Coalition Recommendations’) and building on years of regulatory engagement (ICH Good Clinical Practice guidelines, EU Clinical Trials Regulation), the EHA-led, multidisciplinary, Coalition agreed on a next round of actions including dialogue with sponsors, contract research organizations (CROs) and ethics committees. The collective goal remains to alleviate administrative burdens on investigators and make clinical trials more efficient and patient-centric.

**ASCERTAIN: New cost-benefit, pricing and reimbursement models:** After years of lobbying to get pricing and affordability issues on the European policy agenda, EHA and its partners in the ASCERTAIN consortium received the go-ahead for a four-year, Horizon Europe-funded project that will develop new cost-benefit, pricing and reimbursement models for novel expensive therapies.

**Substances of Human Origin (SoHO) legislation:** Another EU-funded project that kicked off in 2022 is SUPPLY, which aims to strengthen the supply of plasma and plasma-derived medicinal products (PDMPs). EHA leads the development of recommendations on the clinical use of immunoglobulins, particularly in case of shortages. The project results from years of sustained engagement of EHA and the European Blood Alliance in the evaluation and renovation of the EU’s Substances of Human Origin (SoHO) legislation.
ADVOCATING FOR A BETTER FUTURE

Collaboration with other stakeholders is of great importance for effective engagement with EU policymakers and regulators. Support for and joint advocacy with patient organizations and participation in European multistakeholder partnerships are ongoing priorities.

Establishing the EHA Patient Advocacy Committee (PAC)
In June, the EHA PAC was formed, consisting of 14 European umbrella patient organizations committed to improving the lives of patients with hematological disorders. The committee reflects EHA’s long-standing commitment to patient advocacy and is vital for bridging the gap between patients and healthcare providers and for advocating for patients’ needs on a local and global level.

Advancing cellular therapies with diverse stakeholder groups
In 2022, the GoCART Coalition established by EHA and EBMT further advanced its vision of creating a platform driven by input from a diverse group of stakeholders who jointly develop projects advancing the field of cellular therapies in Europe.

Following extensive work by a pharmacists’ expert group in the coalition, a guidance document was developed to harmonize implementation of hospital pharmacy CAR-T services across Europe.

The coalition hosted 10 clinical case discussions and six best practice sharing sessions by nurses, working towards the goal of maximizing the potential of novel cellular therapies.
Initiatives to learn and engage with CAR T-cell patients

Two major initiatives stand out in a year in which the IMI funded (but in-kind) T2EVOLVE’s eight work packages progressed with their work: the launches of the patient hub and the European Patient Survey on CAR T-cell therapy.

The patient hub provides a one-stop-shop of information for CAR T-cell patients carefully curated by the T2EVOLVE consortium. It comprises information from its diverse group of partners ranging from companies to universities, patient organizations and more. By receiving regular updates and its availability in six languages, it is a key step in T2EVOLVE’s strategic objective to involve and guide patients throughout their clinical journey.

This involvement is also at the heart of the European Patient Survey on CAR T-cell therapy, developed alongside QUALITOP and in close collaboration with patient advocacy groups, patients and carers. By further understanding patient experiences, T2EVOLVE can better aim to improve quality of life for patients and their carers.

HARMONY Alliance

Demonstrating the power of Big Data to improve the treatment of Hematologic Malignancies (HMs) through collaborative activities

In the IMI funded HARMONY research projects, scientists, physicians and the pharmaceutical industry team up to produce novel insights into the biology of HMs. They run new algorithms and perform analyses on the thousands of anonymized data sets stored in the HARMONY Big Data Platform to detect relevant patterns. The results may be used to identify high-risk patients with greater reliability and to guide future treatment choices.

By 2022, HARMONY had identified more than 150,000 patient datasets for the HARMONY data lake and transferred more than 73,000 datasets into the HARMONY platform. HARMONY researchers:

- Presented new insights into the prognosis of patients with AML
- Proposed a revision of the international staging system for MM
- Identified gene combinations associated with prognosis in two subtypes of AM
- Found a genetic marker for poor treatment response in adults with a subtype of ALL
- Found factors that contribute to the clinical outcome of AML patients treated prior to the approval of novel drugs
- Identified a low-risk subgroup of ALL that could be considered for treatment reduction
EHA connects the hematology community in Europe and beyond with its annual congress and specialist meetings across hematological fields and in multiple countries. This enables collaboration and opens opportunities for both professional and personal development within hematology. In 2022, we were obliged to remain flexible by organizing virtual, hybrid and in-person meetings.

**Connecting hematologists in Europe and beyond**

The main EHA2022 Congress was our first annual congress in a hybrid format, attracting nearly 17,000 attendees from 122 countries.

Other events included:
- Joint symposia organized at nearly 20 partner society congresses
- Hematology Tutorials in Sri Lanka, Albania, and Turkey
- Highlights of Past EHA focused on the Middle East, Asia, and Latin America, allowing those unable to attend the EHA Congress to interact with past EHA Congress speakers
- Joint Balkan Hematology Day, organized in conjunction with the 33rd National Congress of the Hellenic Society of Hematology (HSH).

**Inaugural EHA Research Conference**

"Extrinsic signals and perturbations in normal and malignant hematopoiesis" was the title of the inaugural EHA Research Conference (ReCon) held in Palermo, Italy. With 25 faculty members and over 140 delegates from across the world present, and rated 9/10 by attendees, the EHA ReCon is poised to become EHA’s premier specialized hematology scientific meeting.

**Gathering top experts from across hematological fields**

In 2022, the Scientific Working Groups changed their name to Specialized Working Groups to better reflect their position as leading research, education and practice-support platforms within specialty fields. Some of their most noteworthy activities include:
- The 4th EHA-EBMT European CAR T-cell Meeting, the leading European event for basic, translational and clinical research in CAR T-cell immunotherapy. The virtual event saw a record number of abstract submissions and 1,640 registrants.
- Meeting on Pediatric Hematology on how to diagnose and treat inherited conditions in children. The event had attendees from over 40 countries and an average rating of 9.2/10.
- Meeting on Transfusion Medicine, aiming to foster and develop research networks for transfusion in Europe.
- Meeting on Integrated Cell Tracking in Oncohematology, presenting state-of-the-art and future directions in laboratory and clinical onco-hematology.
- Virtual Hematology Updates, a webinar series dedicated to a variety of hematology disorders organized by EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT).

**Strengthening the voice of young hematologists**

EHA continues to connect and support junior hematologists in Europe. The YoungEHA Community (less than 37 years) grew to 2,490 members. The Young EHA Research Meeting (YERM) attracted over 520 attendees across five sessions at the EHA Congress.

The Young National Society Ambassadors (YNSA) program, in which each National Society appoints a young hematologist to collaborate on projects, created a Career Mapping Task Force to gain more insight into existing career paths to become a hematologist in different countries.
CONNECTING HEMATOLOGISTS WORLDWIDE

Expansion in members and joint memberships
In 2022, the number of EHA members reached 5,507. EHA launched a new joint membership with the Hellenic Society of Haematology (Greece), adding to the existing joint membership agreements with the Spanish, British, Italian, and Swiss Societies of Hematology.

Fortifying relationships with national societies
One of EHA’s priorities is to intensify its relationships with national societies. A dedicated Community Team was established this year, principally to drive discussions on improving collaboration and service to members. European speakers attended various virtual meetings of national societies around the world, and EHA took advantage of post-pandemic opportunities to meet face-to-face at:

- EHA2022, hosting a networking dinner attended by 21 National Society Presidents or Board representatives;
- the Italian national society’s annual meeting, exhibiting and connecting with attendees;
- EHA Balkan Day, strengthening collaboration in the Balkan region as national society representatives from 12 countries came together.

YoungEHA Research Meeting at EHA2022.

EHA National Societies Dinner at EHA2022.

Program book from the inaugural EHA Research Conference.
HARMONIZING AND BUILDING KNOWLEDGE

EHA is one of the largest international, independent providers of peer-reviewed hematological knowledge. By offering a comprehensive curriculum through the Medical Education Program (MEP), educational materials enabling professionals at all career stages to improve their hematology knowledge, and our high-caliber HemaSphere journal, the organization ensures that we contribute to the latest research and education being available to hematologists at all times.

HemaSphere receives excellent debut impact factor
Disseminating the results of basic, translational and clinical research through our journal HemaSphere is an essential component of our mission. HemaSphere’s continuous publication model means we look for strong studies that report novel findings with high impact in the field of hematology including basic, translational and clinical research. We are also proud to publish timely articles on the practice of hematology. The journal’s biggest milestone to date occurred as it received its debut Journal Impact Factor of 8.3 (source: Clarivate). This placed HemaSphere in the top 15 of all hematology journals.

During the year, HemaSphere launched 12 monthly issues and five official supplements. They contained 132 manuscripts, 42 original articles, 42 letters, and five guidelines.

“[HemaSphere] doesn’t just badge itself as just a clinical journal or just a scientific journal. Our aim is to publish the best and the most relevant articles so it doesn’t matter if they’re scientific, guideline-driven, looking at a rare disease.”

- Claire Harrison, HemaSphere Deputy Editor in Chief

EHA Campus: Virtual Learning Platform
The EHA Campus is a virtual platform that provides a wide range of resources for learners through a range of course formats. The courses are rated highly by participants, with 97% of participants willing to engage in similar courses and 98% recommending them to their colleagues.

The EHA Campus hosts the EHA Unplugged podcast series, EHA2022 spotlight talks, and clinical cases written by hematology experts. The EHA Education department also develops social media learning content in the form of four microlearning programs: LearningMondays, EHA Cases, ThinkingThursdays, and QR Cases.

European Hematology Exam and European Hematology Progress Test
To assess and improve knowledge in hematology, the EHA offers two exams: the European Hematology Exam and the European Hematology Progress Test. Available exclusively to EHA members, the latter is an online learning tool designed to identify knowledge gaps and help members prepare for the European Hematology Exam. In 2022 464 candidates from 39 countries sat the exam successfully.
HARMONIZING AND BUILDING KNOWLEDGE

Lighting the Flame
This program offers mentorship and guidance to medical students, residents, and interns, helping them become familiar with hematology as clinicians and/or researchers. Over 350 individuals have enrolled in the program since summer 2022, and it offers a range of curated content, including QR cases, interviews, podcasts, and materials related to specific illnesses. Of these, a small number will be selected to join a summer school in 2023.

EHA Master Class
This online clinical preceptorship program provides a unique learning opportunity for participants to develop their skills through close contact with senior specialists in groups in which they study five complex hematology clinical cases in-depth over a period of nine months. In 2022, there was a significant increase in the number of mentees, with 90 mentees from 34 countries and 16 mentors from 11 countries. The program enhances the participants’ clinical decision-making skills, critical thinking, and problem-solving abilities.
LOOKING FORWARD TO 2023

Hematology remains an incredibly dynamic field that requires strong involvement with the many stakeholders and groups. The EHA Board and Executive Office gathered in April 2023 to refine and define EHA’s strategic priorities moving forward. A few focus points are worthy of mention:

**Precision Hematology as Topic-in-Focus**

Topic-in-Focus (TiF) status signifies reinforced, multi-departmental significant attention for an appropriate but finite period. As hematology becomes more complex, it is increasingly difficult for hematologists to stay abreast of development and to integrate the avalanche of new tests and treatments across the full spectrum of hematology. This has led to increasing separation between, broadly speaking, non-malignant and malignant diagnostic and therapeutic hematology, at least in academic centers. As treatment is targeted to smaller and smaller patient groups, healthcare systems and training programs have to adapt to this growing complexity, compounded by the arrival of artificial intelligence in the practice of hematology. The precision hematology TiF will aim to identify pragmatic recommendations for evolution of practice in malignant hematology in the Precision Hematology era, hopefully with general guidelines which will extend to non-malignant hematology.

**Clinical Guidelines and recommendations**

Another area where we will further enhance our involvement and influence is the definition and introduction of guidelines. With such a broad member base and our association with other organizations, EHA is in a unique position to leverage its knowledge and strength. As of 2022, 12 EHA clinical practice guidelines were published. These include both EHA-only and collaborative, expert-consensus based or evidence-based guidance on best clinical practice. 13 Guidelines projects are under development and other projects include 9 endorsements, 6 new guideline proposals, 5 recommendations and 6 on-demand workshops, as well as development of the EHA Guidelines app. Increasingly, development of guidelines goes hand in hand with our advocacy work aimed at improving and harmonizing the regulatory environment for clinical practice.

**Expanding our support – and collaborations**

Another consequence of our broad geographic and professional scope is the need to keep a close eye on ensuring fairness for all. As such, diversity, equality and inclusion (DEI) remain important topics in terms of our committees, board and our members. This is also vital as we expand our community, with a focus on member benefits, targeted communications with individual communities and our collaboration with national societies. This growth and outreach also applies to our partnerships – the national societies, regulators, specialized working groups and other associations. There will be a specific focus on facilitating closer involvement of patients through patient delegates in congress planning and education committees. Overall, our political voice needs to be safeguarded by deepening our advocacy and regulatory relations with key bodies such as the EMA.
Digitalization

Finally, we are putting great effort into further development of operational activities, communication, communities of practice and processes. As digitization becomes a critical success factor in serving and connecting with our community, we will be embracing state-of-the-art technological communication aids, and advanced data platforms. This will help us connecting with our members, creating stronger synergies and improving user experiences.

An exciting future together

We are tremendously excited about the future with you. We are very proud of the proactivity of our members and the entire hematology community and plan to welcome an increasing proportion as active contributors. The feedback that we receive on a daily basis is the foundation for our excellency on research, education and advocacy.

Thank you all! Let’s all work together towards optimal care for our patients.
SUPPORTING CAREER DEVELOPMENT AND RESEARCH
The EHA Research Committee (RC) has a new Chair, Prof Brian Huntly, Head of Department and Professor of Leukaemia Stem Cell Biology at the University of Cambridge, UK, and EHA Board member. Prof Shai Izraeli, who chaired the Research Committee through its transition years and the very difficult times of the first COVID-19 pandemic waves, rotated off in June 2021, but accepted to stay on for one year in order to support the transition period. Prof Antonio Almeida replaced Prof Huntly as EHA Board representative in the RC. The RC began implementing new activities approved in the last Investment plan, integrating existing activities with additional grants and training initiatives, new activities like the EHA Research Conferences (EHA ReCon) and an enhanced promotion plan for HemaSphere.

The renewed composition of the EHA RC is the following:

Brian Huntly, Chair
Ruud Delwel, vice-Chair
Arndt Borkhardt, member
Mhairi Copland, member
Thomas Mercher, member
Jessica Okosun, member
Kostas Stamatopoulos, member
Shai Izraeli, additional member
Antonio Almeida, Rep EHA Board
Meritxell Alberich-Jorda, Rep Fellowships & Grants Committee
Adele Fielding, Rep CRTH
Achille Iolascon, Rep SWG Committee
Anna Kabanova, Rep YoungEHA Committee
Veronika Sexl, Rep TRTH
Martina Muckenthaler, Rep HemaSphere Editorial Board
EHA GUIDELINES

EHA promotes excellence in patient care in hematology directly by developing clinical practice guidelines for the diagnosis and treatment of hematologic diseases. Since its establishment in 2019, EHA Guidelines have rapidly developed into a key EHA activity.

EHA Guidelines connect hematology experts to develop and publish clinical practice guidelines on the European level and beyond. EHA also enhances clinical guidelines through collaborations with both national and international medical associations and societies.

As of 2022, 12 EHA clinical practice guidelines were published. These include both EHA-only and collaborative, expert consensus-based, or evidence-based guidance on best clinical practice.

13 Guidelines projects are under development and other projects include 9 endorsements, 6 new Guidelines proposals, 5 recommendations, 6 on-demand workshops, as well as the development of an EHA Guidelines app.

EHA GUIDELINES: PUBLISHED

In 2022, EHA published 5 clinical practice guidelines:

AL Amyloidosis (EHA-ISA project)

Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group

Bleeding and thrombosis (EHA project)

EHA Guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer

Anemia (EHA-BSH project)

The Use of Next-generation Sequencing in the Diagnosis of Rare Inherited Anaemias: A Joint BSH/EHA Good Practice Paper

Infections (EHA project)

Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association

Cardiovascular toxicity of anti-cancer treatments (ESC-EHA-ESTRO-IC-OS project)

ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
In 2022, EHA continued 10 guidelines projects from 2021 and launched three new ones:

<table>
<thead>
<tr>
<th>GUIDELINES TITLE</th>
<th>TYPE</th>
<th>SWG(S)/OTHER ORGANIZATIONS/NETWORKS INVOLVED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient-reported outcomes measurement in hematology</td>
<td>Evidence-based</td>
<td>SWG(s): Quality of life, Aging in Hematology</td>
</tr>
<tr>
<td>Cardiovascular toxicity in older adults with hematologic malignancies</td>
<td>Evidence-based</td>
<td>SWG: Aging in Hematology</td>
</tr>
<tr>
<td>Cytopenias in the elderly</td>
<td>Consensus-based</td>
<td>SWG(s): MDS, GCMFS, Lymphoma Group, Red Cells&amp; Iron, Aging in Hematology, Thrombocytopenias, Platelet Function Disorders</td>
</tr>
<tr>
<td>Diagnosis and Management of Chronic Neutropenias</td>
<td>Evidence/Consensus-based</td>
<td>Eunet-INNOCHRON</td>
</tr>
<tr>
<td>Treatment of Chronic Neutropenias</td>
<td>Evidence/Consensus-based</td>
<td>Eunet-INNOCHRON</td>
</tr>
<tr>
<td>Antithrombotic Treatment in Patients with Hemophilia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse large B-cell lymphoma</td>
<td>Consensus-based</td>
<td>European Society for Medical Oncology (ESMO)</td>
</tr>
<tr>
<td>Primary CNS lymphomas</td>
<td>Consensus-based</td>
<td>ESMO</td>
</tr>
<tr>
<td>Peripheral T-cell lymphomas</td>
<td>Consensus-based</td>
<td>ESMO</td>
</tr>
<tr>
<td>HIV lymphomas</td>
<td>Consensus-based</td>
<td>ESMO</td>
</tr>
<tr>
<td>New: Pediatric MDS</td>
<td>Consensus-based</td>
<td>EWOG-MDS</td>
</tr>
<tr>
<td>New: Van Willebrand disease (part of the MBDs)</td>
<td>Evidence-based</td>
<td>EAHAD</td>
</tr>
<tr>
<td>New: Coagulation and Fibrinolysis (part of the MBDs)</td>
<td>Evidence-based</td>
<td>EAHAD</td>
</tr>
</tbody>
</table>
At the EHA2022 Congress, EHA presented nine Guidelines. These sessions were live, virtual, and featured an overview of the guidelines by a lead author, a patient case presentation to illustrate the applicability of the guidelines in the real-world setting, and concluded with an interactive panel discussion based on the participants’ questions.

**EHA2022 CONGRESS GUIDELINES SESSIONS**

<table>
<thead>
<tr>
<th>DATE</th>
<th>GUIDELINES</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 15, 2022</td>
<td>Multiple Myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up</td>
</tr>
<tr>
<td>June 15, 2022</td>
<td>EHA-EuroBloodNet Methemoglobinemia Guidelines</td>
</tr>
<tr>
<td>June 15, 2022</td>
<td>ISA-EHA non-transplant therapy Guidelines</td>
</tr>
<tr>
<td>June 15, 2022</td>
<td>EHA-EuNet-INNOCHRON Guidelines on Chronic Neutropenias</td>
</tr>
<tr>
<td>June 15, 2022</td>
<td>ISA-EHA stem cell transplant Guidelines</td>
</tr>
<tr>
<td>June 15, 2022</td>
<td>BSH-EHA Guidelines on use of next-generation sequencing in the diagnosis of congenital anemias</td>
</tr>
<tr>
<td>June 16, 2022</td>
<td>EHA Guidelines on antifungal prophylaxis and therapy in patients with AML treated with new agents</td>
</tr>
<tr>
<td>June 16, 2022</td>
<td>EHA Guidelines on management of anti-thrombotic treatment in thrombocytopenic patients with cancer</td>
</tr>
<tr>
<td>June 17, 2022</td>
<td>EHA Endorsement of the MDS-RIGHT Guidelines</td>
</tr>
</tbody>
</table>

**EHA GUIDELINES APP**

In June 2022, EHA initiated the development of an EHA Guidelines mobile app. The app has undergone multiple rounds of technical improvements, and as of December 2022 is in beta testing. The launch is currently scheduled for the second quarter of 2023. Current features include:

- 4 pilot EHA Guidelines (with associated PDF links)
- 6 interactive tools
- Guidelines workshops
- Interactive menu with app feedback options
HemaSphere

EHA’s official journal, HemaSphere, publishes results of highly relevant basic, translational, and clinical research in hematology. The journal is especially interested in strong studies reporting novel findings that are of high impact to the field of hematology. HemaSphere is the premier hematology information resource, and is enhanced by the HemaTopics section of the journal, featuring insightful discussions on all aspects related to hematology such as summaries of important articles, reports of new therapies, discussions on European policy, and more.

HemaSphere is guided by an international, expert Editorial Board, offers a fast and constructive review process, and maintains low article processing fees. The journal officially releases 12 primary issues per year but publishes a steady flow of new content via its continuous online publishing schedule. HemaSphere is an online, fully open access journal, dedicated to supporting hematology patient care, research, and education worldwide.

2022 MILESTONES

Leadership

In 2021, HemaSphere transitioned from a bimonthly to monthly issue schedule, launching 12 regular issues and 2 supplements. Below, the breakdown of publications per type is illustrated. By the end of 2021, HemaSphere published 153 manuscripts.

- HemaSphere’s esteemed Co-Editor in Chief, Andreas Engert, rotated from the journal’s leadership in June 2022. Prof Engert served in this role from the beginning of HemaSphere’s existence in 2017, and the journal and EHA are forever indebted to him for his expertise, dedicated service, and leadership.
- In July 2022, HemaSphere was thrilled to welcome Claire Harrison as the new Deputy Editor in Chief of the journal. Prof Harrison previously served as a HemaSphere Associate Editor starting in 2017. The journal and EHA welcomes Prof Harrison’s leadership and expertise.
- While the end of 2022 marked the close of an existing service term for HemaSphere Co-Editor in Chief, Jan Cools, the journal and EHA were pleased to confirm Prof Cools for a new term, serving as Editor in Chief, starting January 2023. Prof Cools has been a driving force for HemaSphere since the beginning, and the team is grateful for his continued dedication and guidance ahead.
Publishing Statistics:

HemaSphere launched 12 monthly issues and 5 official supplements in 2022.

Overall, 132 manuscripts were published in 2022, which was a slight decrease from 2021 and an acceptable variation. Of the 2022 publications, there were 42 original articles, 42 letters, and 5 guidelines.

The average time to first decision was 21 days.
2022 brought *HemaSphere* its biggest milestone to date – the journal was delighted to receive its debut Journal Impact Factor of 8.3 (source: Clarivate). This placed *HemaSphere* in the top 15 of 78 hematology journals.

**Increasing Citations:**

The journal is pleased to receive a continued increase in citations, tracked via Web of Science.

**HemaSphere social media:**

The *HemaSphere* Twitter account [@HemaSphere_EHA](https://twitter.com/HemaSphere_EHA), launched mid-2020, has grown exponentially, exceeding the 3000-follower mark before 2022 closed. Via regular tweets of its publications, *HemaSphere* has successfully expanded its exposure across the scientific community.

In mid-2022, the *HemaSphere* LinkedIn account launched. Connections to this page and interactions with the journal’s posts are steadily growing.

*HemaSphere* publishes continuously online, including a monthly compendium launch. Each monthly compendium table of contents (with links the journals’ fully open access publications) is emailed to the EHA email network; please let EHA or *HemaSphere* know if you would like to opt in and receive these once per month email alerts.
EHA GRANTS
2022

EHA focuses on accelerating the career of promising researchers in hematology by providing EHA Research Grants, funding lab-based research of talented early-career researchers and physician-scientists.

EHA Grants are open to candidates of any nationality, but the home or host institute must be an academic research center or proven equivalent, and one of them must be located in Europe.

The Fellowships & Grants Committee (F&GC) is responsible for reviewing all applications and selecting talented researchers to be awarded an EHA Grant.

F&GC and the EHA Executive Office would like to thank all the external reviewers who have been involved in the review process for Research Grants and Bilateral Collaborative Grants.

RESEARCH GRANTS

EHA Research Grants support talented junior researchers in advancing their career, e.g. towards becoming the leader of a research group.

The call for Research Grants opened in September 2021 and closed in December 2021, and was awarded to eight projects in May 2022 after undergoing two rounds of review (internal and external) and interviews.

In 2022, the following grants were awarded:

- 2 Junior Research Grants: €50,000 per year, for 3 years
- 3 Advanced Research Grants: €80,000 per year, for 2 years
- 1 Physician Scientists’ Research Grants: €80,000 per year, for 2 years
- 1 Topic-in-Focus Junior Research Grants: €50,000 per year, for 3 years
- 1 Topic-in-Focus Advanced Research Grants: €80,000 per year, for 2 years
The following early career researchers received EHA Research Grants in 2022.

<table>
<thead>
<tr>
<th>NAME</th>
<th>CATEGORY</th>
<th>PROJECT TITLE</th>
<th>INSTITUTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandre Fagnan</td>
<td>Junior Research Grant</td>
<td>Deciphering the chromatin remodeling mechanism mediated by GATA2 ZnF1 mutations in AML.</td>
<td>University of Oxford, United Kingdom</td>
</tr>
<tr>
<td>Samuele Ferrari</td>
<td>Junior Research Grant</td>
<td>Innovative targeted base editing strategies for gene correction of WHIM syndrome.</td>
<td>Ospedale San Raffaele, Italy</td>
</tr>
<tr>
<td>Lars Velten</td>
<td>Advanced Research Grant</td>
<td>The role of the DNA methylation landscape in regulating HSC fate biases, fate restriction, and lineage differentiation.</td>
<td>Centre for Genomic Regulation, Spain</td>
</tr>
<tr>
<td>Özgen Deniz</td>
<td>Advanced Research Grant</td>
<td>Functional Interrogation of Transposable Elements in Paediatric Acute Myeloid Leukaemia</td>
<td>Queen Mary University of London, United Kingdom</td>
</tr>
<tr>
<td>Emma de Pater</td>
<td>Advanced Research Grant</td>
<td>Deconstructing the effect and timing of GATA2 haploinsufficiency driven leukemogenesis.</td>
<td>Erasmus MC, the Netherlands</td>
</tr>
<tr>
<td>Bérengère Koehl</td>
<td>Physician Scientists' Research Grant</td>
<td>Abnormal Myelopoiesis in Sickle cell disease promotes neutrophils dysfunction, inflammation and early hematopoiesis ageing.</td>
<td>Université de Paris, France</td>
</tr>
</tbody>
</table>
The Topics-in-Focus program was launched by EHA to support hematologists in this rapidly developing scenario, aiming to raise awareness, provide education, further research, and build a network of experts in specific fast-growing areas. In 2022, EHA awarded two Topics-in-Focus grants meant for quality basic or translational research projects in the field of immunotherapy. The talented recipients of these grants are from institutes in France and the Netherlands.

**TOPICs-IN-FOCUS GRANTS**

<table>
<thead>
<tr>
<th>NAME</th>
<th>CATEGORY</th>
<th>PROJECT TITLE</th>
<th>INSTITUTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Marijn Kramer</td>
<td>Topic-in-Focus Junior Research Grant (Immunotherapy)</td>
<td>Study of CAR T-Cell Associated Toxicity and Efficacy: Mechanisms, Clinicopathologic Correlates, and state-of-the art nanomedicine-based targeting of myeloid immune cells as a novel therapeutic strategy.</td>
<td>Amsterdam University Medical Center, the Netherlands</td>
</tr>
<tr>
<td>Arnika Wagner</td>
<td>Topic-in-Focus Advanced Research Grant (Immunotherapy)</td>
<td>Novel chimeric antigen receptors for optimized NK cell function.</td>
<td>Karolinska Institutet, Sweden</td>
</tr>
</tbody>
</table>

**KICK-OFF GRANTS**

Kick-off Grants support basic and translational early-career researchers in hematology and allow them to test a high-risk but potentially high-impact idea that lacks solid preliminary data and is therefore too premature to submit for regular funding. The Grant is worth up to €50,000 for one year. The second edition of the KOG call opened on June 1, 2021 and closed on September 12, 2021. Recipients of the grant were confirmed in 2022.
We congratulate the six early-career researchers awarded this grant:

<table>
<thead>
<tr>
<th>NAME</th>
<th>CATEGORY</th>
<th>PROJECT TITLE</th>
<th>INSTITUTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diana Campillo Davo</td>
<td>Kick-Off Grant</td>
<td>START project: Self-amplifying RNA-engineered T cells for Anti-leukemic Redirected Therapy</td>
<td>University of Antwerp, Belgium</td>
</tr>
<tr>
<td>Emilie ELVIRA-MATELOT</td>
<td>Kick-Off Grant</td>
<td>Clonal Hematopoiesis of Indeterminate Potential (CHIP): role of heterochromatin disorganization and Transposable Element Activation?</td>
<td>INSERM, France</td>
</tr>
<tr>
<td>Flavian Thelen</td>
<td>Kick-Off Grant</td>
<td>Regulation of Hematopoietic Stem Cells by Bone Marrow Memory CD8 T Cells</td>
<td>University of Zurich, Switzerland</td>
</tr>
<tr>
<td>Ginés Luengo-Gil</td>
<td>Kick-Off Grant</td>
<td>CAR macrophages with sustained M1 phenotype: deceiving the tumor immunosuppressive microenvironment with deception receptors.</td>
<td>Hospital General Universitario Santa Lucia, Spain</td>
</tr>
<tr>
<td>Hector Huerga Encabo</td>
<td>Kick-Off Grant</td>
<td>Kicking of the contribution of “Preleukemic Dendritic Cells” in clonal hematopoiesis associated pathologies</td>
<td>The Francis Crick Institute, United Kingdom</td>
</tr>
<tr>
<td>Roeland Klein Wolterink</td>
<td>Kick-Off Grant</td>
<td>NeuroNK - Neuronal control of natural killer cells</td>
<td>Maastricht University, The Netherlands</td>
</tr>
</tbody>
</table>
Bilateral Collaborative Grants (BCG) encourage and support collaboration between two independent research groups in basic/translational hematology research located in two different European countries.

The first call for the Bilateral Collaborative Grants opened in June and closed in September 2021 and was awarded to two projects in April 2022 after undergoing two rounds of review (internal and external) and interviews. After this process, two proposals were awarded.

We congratulate the first BCG winners.

**Project Title: Dissecting the role of transposable element-mediated inflammation in human hematopoietic stem cell development**

Name: Andrea Ditadi  
Institute: Ospedale San Raffaele, Italy

Name: Eirini Trompouki  
Institute: Institute for Research on Cancer and Aging, Nice (RCAN), France

**Project Title: Proteogenomic guidance for the treatment of high-risk acute lymphoblastic leukemia**

Name: Ashok Kumar Jayavelu  
Institute: Hopp Children’s Cancer Center (KiTZ), University Hospital Heidelberg, Germany

Name: Beat Bornhauser  
Institute: University Children’s Hospital Zurich, Switzerland
**RESEARCH MOBILITY GRANTS**

EHA strives to develop the careers of young scientists by supporting mobility and facilitating a visit to a research group in another institute. Both institutes should have complementary expertise as this visit is intended to promote collaboration between the institutes. These grants have a low threshold for application but a quick turnaround in review and selection. The call is open throughout the year.

After several months on hold due to the travel uncertainties caused by the COVID-19 pandemic, the call was restarted in 2022. A high number of applications were received and reviewed by the Fellowships & Grants committee.

The following 11 proposals were awarded an EHA Research Mobility Grant:

<table>
<thead>
<tr>
<th>NAME</th>
<th>CATEGORY</th>
<th>PROJECT TITLE</th>
<th>HOME</th>
<th>HOST INSTITUTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahmed Ludvigsen Al-Mashhadi</td>
<td>Research Mobility Grant</td>
<td>Long-term outcomes in patients with SMZL treated in the Rituximab Era</td>
<td>Aalborg University, Denmark</td>
<td>University of British Columbia, Canada</td>
</tr>
<tr>
<td>Ainhoa Goñi Salaverri</td>
<td>Research Mobility Grant</td>
<td>Characterisation of Genome Regulatory Complexes in Haematopoiesis and Leukaemia</td>
<td>University of Navarra, Spain</td>
<td>CRUK Cambridge Major Centre, United Kingdom</td>
</tr>
<tr>
<td>Dino Mehic</td>
<td>Research Mobility Grant</td>
<td>Fibrinolysis in patients with mild to moderate bleeding tendency</td>
<td>Medical University of Vienna, Austria</td>
<td>University of North Carolina, United States</td>
</tr>
<tr>
<td>NAME</td>
<td>CATEGORY</td>
<td>PROJECT TITLE</td>
<td>HOME INSTITUTE</td>
<td>HOST INSTITUTE</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Elena Monzón Manzano</td>
<td>Research Mobility Grant</td>
<td>Role Of Platelet Glycosylation On Platelet Function And Immune Response In Immune Thrombocytopenia Patients</td>
<td>Hospital La Paz Institute for Health Research (IdiPAZ), Spain</td>
<td>Imperial College of London, United Kingdom</td>
</tr>
<tr>
<td>Eric Amelunxen</td>
<td>Research Mobility Grant</td>
<td>Functional drug response profiling to identify age-specific vulnerabilities in KMT2A rearranged ALL</td>
<td>Christian-Albrechts-Universität Kiel, Germany</td>
<td>UZH Kinderspital Zurich, Switzwerland</td>
</tr>
<tr>
<td>Gils Roex</td>
<td>Research Mobility Grant</td>
<td>Learning the design language of CAR structural components using a high-throughput screening method</td>
<td>University of Antwerp, Belgium</td>
<td>Massachusetts Institute of Technology, United States</td>
</tr>
<tr>
<td>Katerina Miari</td>
<td>Research Mobility Grant</td>
<td>Macrophage Elicited Therapy Resistance in Acute Myeloid Leukaemia</td>
<td>Glasgow Caledonian University, United Kingdom</td>
<td>Cornell University, United States</td>
</tr>
<tr>
<td>NAME</td>
<td>CATEGORY</td>
<td>PROJECT TITLE</td>
<td>HOME INSTITUTE</td>
<td>HOST INSTITUTE</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Maria Queralt Salas</td>
<td>Research Mobility Grant</td>
<td>Frailty Evaluation in Patients Eligible for Hematopoietic Cell Transplantation</td>
<td>University of Barcelona. Hospital Clinic de Barcelona, Spain</td>
<td>Princess Margaret Cancer Center, Canada</td>
</tr>
<tr>
<td>Mohammadsadegh Nadimifar</td>
<td>Research Mobility Grant</td>
<td>Human Hemoglobin Immobilization on Albumin Nanoparticle for Oxygen Carrier synthesis</td>
<td>University of Tehran, Iran</td>
<td>Technical University of Denmark, Denmark</td>
</tr>
<tr>
<td>Noa Linthorst</td>
<td>Research Mobility Grant</td>
<td>Personalized gene-targeted treatment strategies for the management of the complex genetic bleeding disorder Von Willebrand Disease</td>
<td>Leiden University Medical Center, The Netherlands</td>
<td>INSERM, France</td>
</tr>
<tr>
<td>Srdjan Grusanovic</td>
<td>Research Mobility Grant</td>
<td>Effects of acute inflammation on iron metabolism in HSCs</td>
<td>Institute of Molecular Genetics, Czech Republic</td>
<td>Albert Einstein College of Medicine, United States</td>
</tr>
</tbody>
</table>
TALENT ACCELERATOR
MENTORING PROGRAMS

EHA mentoring programs are a unique opportunity to engage with peers and faculty and to learn from each other, not only in the formal classroom but also around a dinner table or during a coffee break.

After two years with mentoring programs on pause due to the restrictions imposed by the COVID-19 pandemic, in-person mentoring programs were restarted in 2022.

EHA-EMBL/EBI COMPUTATIONAL BIOLOGY TRAINING IN HEMATOLOGY (CBTH)

Computational Biology Training in Hematology (CBTH) is a joint effort of the European Hematology Association (EHA) and the European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI) that supports the development of quantitative skills for hematology researchers in computational biology, filling a critical gap in the field. This is a new program, which engages with a different audience than the mentoring programs currently offered by EHA.

The inaugural call for applications was opened in June 2022. Dr Peter Campbell from the Wellcome Sanger Institute and Dr Aziz Mithani, scientific training lead from EMBL-EBI, are the current co-directors. The selection process for applicants was completed at the end of 2022, with an exciting class of 20 scholars selected to attend the first workshop in 2023.

The EHA Talent Accelerator team would like to thank Joint Oversight Committee members for their guidance in designing the program and faculty who accepted invitations to join this new and exciting mentoring program.

CLINICAL RESEARCH TRAINING IN HEMATOLOGY (CRTH)

Through Clinical Research Training in Hematology, EHA provides early career researchers with a nine-month long unique training and mentoring experience focused on clinical research in Europe, with a global scope. The program consists of two multi-day workshops at different locations in Europe and includes a variety of teaching and learning experiences, including self-directed learning, one-to-one mentoring by experts, plenary sessions, and peer working groups, focusing on individual topics of interest and expertise.

The 6th edition of CRTH was under the guidance of Course Directors Prof Adele Fielding and Prof Carol Moreno. We would like to thank all the faculty who were involved in making this course a success.
EHA-ASH TRANSLATIONAL RESEARCH TRAINING IN HEMATOLOGY (TRTH)

EHA-ASH TRTH provides early-career researchers with a unique, year-long training and mentoring experience. TRTH is a joint effort of EHA and the American Society of Hematology (ASH) and is focused on helping early-career hematological scientists build successful careers in translational research.

The TRTH program begins with an intensive week-long course held in the spring.

Mornings are dedicated to didactic and interactive sessions that further participants’ understanding of translational research methodology and career development. Afternoons are devoted to small group sessions in which participants meet with their TRTH mentors, peers, and faculty to refine their individual research proposals. Informal presentations by leaders in hematology, designed to illustrate the variety of pathways to a successful career in hematology research, take place in the evenings.

The class of 2020-2022 has undergone multiple delays and deferrals as it was most impacted by the COVID-19 pandemic and travel restrictions. The class met virtually in 2021 in several online sessions run by TRTH faculty and, finally, in person in 2022.

EHA thanks the Course Directors, Prof Elizabeth Macintyre and Prof Janis Abkowitz for their leadership throughout the course, as well as all faculty who dedicated their time and ensured this class was a success.

Congratulations to all 20 scholars who have been engaged in the whole process: Alba Maiques-Diaz; Anastasia Conti; Anjali Cremer; Dagmar Gotthardt; Erin Parry; Hsuan-Ting Huang; Jacob Appelbaum; Jolanda Sarno; Konstantinos Kokkaliaris; Lina Benajiba; Maria Eugenia de la Morena-Barrio; Miriam Kim; Mirjam Belderbos; Misuk Bae; Ofrat Beyar Katz; Samuli Eldfors; Sarah Gooding; Simona Valletta.

CRTH 2023 Scholars: Alessandra Romano; Anjum Khan; Anne Sophie Kubasch; Catherine Rockings; Claudia Stege; Elias Mai; Giulia Prunotto; Jakub Krejcik; Janine Stutterheim; Justin Ferdinandus; Mandy Lauw; Marie-Emilie Dourthe; Marius Bill; Michael Ozga; Nicola Maciocia; Nicolas Martinez-Calle; Selina Chavda; Semih Başçi; Suzanne Arulogun; Vinicius de Molla.

We look forward to the new edition of 2023, which will be led by Prof Mhairi Copland and Prof Bjørn Tore Gjertsen.
EHA strives to support career development of young researchers, but how can this be monitored? Measuring this impact should go beyond merely tracking publication records and this is why we have started working with ResearchFish.

ResearchFish is used globally by funders and universities to track research and evidence impact. The platform uses technology and algorithms to collect outcomes and outputs of research from the web, external data sources, and the researchers themselves.

Recipients of EHA grants and participants in the EHA mentoring programs are encouraged to submit an entry via ResearchFish annually, allowing us to monitor programs and course correct when needed.

We would like to thank all past-trainees and grant winners who have completed the survey.
ADVOCATING FOR A BETTER FUTURE

“REPRESENTING HEMATOLOGY AND HEMATOLOGISTS IN EUROPE”
AWAReNESS, ADVOCACY, AND STAKEHOLDER RELATIONS

EHA serves as the voice of hematologists in Europe, working to raise awareness of their contribution to healthcare and health research, and to promote their specific needs and interests. To be an effective advocate for hematology professionals and their patients, EHA interacts and collaborates with key stakeholders, taking an integrated approach to policy, regulatory, and scientific relations.

ADVOCACY PRIORITIES

EHA’s policy and lobbying activities are based on three overarching priorities:

• Support for hematology research (increased funding and improved governance),
• Access to affordable diagnostics and treatment for patients with blood disorders,
• An optimized regulatory framework in line with the needs of hematology and hematologists.

STAKEHOLDER RELATIONS

At the basis of EHA’s policy and advocacy work is proactive and sustained engagement and alignment with patient organizations, nurses, EU institutions, industry partners, and national hematology societies. Active participation in alliances and EU-funded projects is an integral part of our stakeholder strategy.

HIGHLIGHTS 2021:
EU PHARMACEUTICAL AND HEALTH POLICIES

Rising pressures on European health systems resulting from the COVID-19 pandemic, the fight against cancer, and the costliness of many novel therapies have accelerated the development and revision of EU policies, legislation, and funding programs in health. EHA engaged with EU institutions and stakeholders to ensure that the views and needs of hematologists, particularly regarding access to innovative therapies, found their way into key EU initiatives, such as:

• Revision of the EU pharmaceutical and orphan drugs legislation,
• EU funding programs, in particular Horizon Europe and EU4Health,
• The new EU HTA Regulation,
• The Europe’s Beating Cancer Plan.

Together with its allies (other medical societies, patient organizations), EHA was instrumental in securing a prominent place in these EU initiatives for key topics such as personalized medicine, unmet needs, precision diagnostics, affordability of cell and gene therapies, and real-world evidence generation.

To increase the visibility of hematology and magnify the voice of hematologists in the cancer stakeholder landscape, EHA joined the European Cancer Organisation as well as the multistakeholder advocacy collaborative Rare Cancers Europe at the start of 2021.
REDUCING BUREAUCRACY IN CLINICAL TRIALS

One particularly high-profile and high-impact activity at the European level is the (EHA initiated and led) campaign to reduce unnecessary and potentially harmful administrative burdens for investigators and participants in clinical trials. The Recommendations of the Coalition for Reducing Bureaucracy in Clinical Trials ('Coalition Recommendations') were published in November 2021. Key concerns and recommendations of the Coalition on safety reporting, ethics requirements, and regulatory guidance have already been incorporated in the revision of the ICH E6 GCP guidelines, the draft guidance of the Good Clinical Trials Collaborative, and, crucially, the implementation of the EU Clinical Trials Regulation.

IN VITRO DIAGNOSTICS REGULATION (IVDR) AND PRECISION DIAGNOSTICS

The BioMed Alliance IVDR Taskforce, chaired and represented in the EU’s Medical Devices Coordination Group by EHA President Elizabeth Macintyre, won an important first achievement for the academic diagnostic community with the European Commission’s October 2021 announcement that application of key IVDR requirements would be postponed and rolled out progressively between May 26, 2022 and 2028.

In December, the BioMed Alliance published the results of a survey, designed and overseen by the EHA Taskforce on IVD, on the current use of IVD tests and IVDR preparedness among diagnostic laboratories.

HEALTH TECHNOLOGY ASSESSMENT (HTA) REGULATION

Having lobbied actively for an EU mechanism for joint HTA, with structural involvement of clinicians and patients, EHA is finding itself positioned in the front-row of HTA regulation following the December 2021 adoption of the EU HTA Regulation. Both EHA and the BioMed Alliance (for which EHA has co-led on the topic) have been invited to join the stakeholder framework for implementation of the HTA Regulation. EHA has advocated for an important role for medical societies, with timely selection and consultation of experts, which is crucial for ensuring the quality and uptake of joint clinical assessments which, in turn, will improve efficiency, reduce cost, and increase access to treatments with demonstrated clinical and patient benefits.

EUROPEAN MEDICINES AGENCY (EMA)

Throughout 2021, EHA continued to invest in the strengthening of a constructive, mutually beneficial collaboration with EMA. Among the collaborations’ results were the first EHA-EMA Joint Symposium at EHA’s Annual Congress, involvement in a new EMA policy-level stakeholder group, and participation in a structured dialogue between EMA and academia on optimization of cancer medicines.
DEMONSTRATING THE POWER OF BIG DATA TO IMPROVE THE TREATMENT OF HEMATOLOGIC MALIGNANCIES (HMS) THROUGH COLLABORATIVE ACTIVITIES

Advancing the understanding of blood cancers

In HARMONY research projects, scientists and physicians team up to produce novel insights into the biology of HMSs. They run new algorithms and perform analyses on thousands of anonymized data sets stored in the HARMONY Big Data Platform to detect relevant patterns. The results may be used to identify high-risk patients with greater reliability and to guide future treatment choices. In 2022, HARMONY researchers:

- presented new insights into the prognosis of patients with acute myeloid leukemia (AML)
- proposed a revision of the international staging system for multiple myeloma (MM)
- identified gene combinations associated with prognosis in two subtypes of AML
- found a genetic marker for poor treatment response in adults with a subtype of acute lymphoblastic leukemia (ALL)
- found factors that contribute to the clinical outcome of AML patients treated prior to the approval of novel drugs
- identified a low-risk subgroup of ALL that could be considered for treatment reduction

Developing Core Outcome Sets

Defining a Core Outcome Set (COS) for HMSs may improve the interpretation and comparability of clinical trials, especially if the COS addresses all stakeholders’ needs.

In 2022, an overarching COS for AML, non-Hodgkin lymphoma (NHL), myelodysplastic syndromes (MDS), MM, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), myeloproliferative neoplasms (MPN), Hodgkin lymphoma (HL), and Waldenström macroglobulinemia (WM) was presented. The COS was defined using a novel Delphi Hackathon approach.

Organizing multi-stakeholder projects

The HARMONY Alliance is running Health Technology Assessment projects and organizing multi-stakeholder activities. In 2022, HARMONY experts concluded that value frameworks currently used to evaluate the clinical value of novel therapies for HMSs make insufficient use of routine care data and patient-reported outcomes.

Consolidating our infrastructure

The HARMONY Alliance Big Data Platform facilitates state-of-the-art blood cancer research. Careful procedures ensure the anonymization and quality of data, and HARMONY data scientists have developed sophisticated methods for data harmonization and analysis. In 2022, HARMONY identified more than 150,000 patient datasets for the HARMONY data lake and transferred more than 73,000 datasets into the HARMONY platform.

Read about the 2022 highlights on the detailed HARMONY web page.
With 5,540 members in 2022, the number of EHA members increased by 14.7% compared to 2021. The main membership base is situated in Europe, accounting for almost 77% of our members.

In 2022, joint memberships with various National Hematology Societies in Europe were prolonged. Members of the Spanish, British, Italian, and Swiss Societies of Hematology can make use of the joint membership. Additionally, a new joint membership with the Hellenic Society of Haematology (Greece) was launched. In 2023, EHA will further support hematologists by launching new joint memberships with national societies in France, Israel, Kazakhstan and Australia & New Zealand.

Membership was promoted via different communication channels such as the website, promotional emails, and congress. During and after the virtual EHA Congress in June, members are given a 50% discount with the possibility of becoming members until the end of the year.

<table>
<thead>
<tr>
<th>TYPE OF MEMBERSHIP</th>
<th>NUMBER OF MEMBERS IN 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EHA-SEHH Joint Membership (Spain)</td>
<td>315</td>
</tr>
<tr>
<td>EHA-BSH Joint Membership (UK)</td>
<td>146</td>
</tr>
<tr>
<td>EHA-SIE Joint Membership (Italy)</td>
<td>116</td>
</tr>
<tr>
<td>EHA-SSH Joint Membership (Switzerland)</td>
<td>81</td>
</tr>
<tr>
<td>EHA-HSH JOINT MEMBERSHIP (GREECE)</td>
<td>38</td>
</tr>
</tbody>
</table>
In 2022, Europe had the highest percentage of members at 74.86%, followed by North America at 10.63%, Asia at 6.99%, Oceania at 3.92%, Africa at 1.71%, and South America at 1.90%.
EHA partners with Specialized Working Groups (SWGs) to foster science and spread knowledge in basic, translational, and clinical research in hematology in Europe. Currently, there are 24 SWGs, covering both disease-oriented and overarching topics.

**SWG INVOLVEMENT IN EUROPEAN AFFAIRS INITIATIVES**

SWG involvement in European Affairs activities is crucial. Three interactions between EHA SWGs and the EHA European Affairs initiatives can be highlighted:

- **EuNet-INNOCHRON**, European Network for Innovative Diagnosis and Treatment of Chronic Neutropenias, is a COST Action chaired by Helen Papadaki and Carlo Dufour, chairs of the EHA SWG on Granulocytes and Constitutional Marrow Failure Disorders.
- SWGs were asked to raise awareness on the impact that the new In Vitro Diagnostic medical devices Regulation (IVDR) will have on hematology labs. For this, the EHA Office created a flyer, together with the EHA Taskforce on IVD, chaired by Jacques van Dongen, chair of the EHA SWG ESLHO, and whose members include the chairs of the SWG on AML, Transfusion, and Diagnostics.
- EHA recently established the **EHA Taskforce for Adolescents and Young Adults with Hematologic Diseases**, which aims to oversee the various interactions with AYA stakeholders and EU policymakers, ensure coherence, and provide input or formulate EHA’s position where needed. Adolescents and Young Adults (AYA) with hematologic diseases are a unique group with special characteristics and needs. Although in recent years the challenges related to the management of AYA (particularly in relation to cancer) are increasingly recognized, more knowledge, awareness and a continuous collaboration between pediatric and adult hematologists are needed to better address the specific needs of AYA with hematologic diseases.
SWG BUSINESS MEETINGS

Every year, SWGs are invited to hold SWG Business Meetings. The SWG Business Meetings are commonly used to update SWG members on the status of the SWG internal activities, but can also be used to:

- Disseminate scientific information and updates in the field
- Coordinate participation in EHA initiatives and collaborations with other groups/networks
- Prepare attendees for the EHA Congress (recommended sessions, etc.), if the meeting takes place before the congress
- Provide highlights of the congress if the meeting takes place after the congress

SWG FRAMEWORK

A new SWG Framework was developed to harmonize and support both EHA and SWG efforts to follow the common mission “Towards a cure for all blood disorders”. The objectives of the new framework are:

- Support a network of experts
- Establish a platform for collaboration
- Produce, translate and disseminate novel knowledge and basic research principles and treatment
- Ensure interaction and cohesion
- Create network of related specialties (cardiologists, surgeons, gynecologists, etc.)
- Develop continuing medical education for hematology professionals

The EHA Executive Office will implement this SWG framework in 2023 to align with all SWGs.

SCIENTIFIC MEETINGS

4TH EHA-EBMT EUROPEAN CAR T-CELL MEETING

February 10-12, 2022 | Virtual

*Chair*: Prof M Hudecek (DE), I Yakoub-Agha (FR), J Gribben (UK), N Kröger (DE)

Now established as a prime event in Europe for basic, translational, and clinical research in CAR T-cell immunotherapy, EHA and EBMT proudly presented the 4th edition of the European CAR T-cell Meeting. Although originally planned as a hybrid meeting, due to the global COVID-19 pandemic and surge of infections across Europe, it was decided to convert the meeting to a fully virtual event.

The program included keynote lectures, interactive debate sessions and more. The program was created for physicians, nurses, and patient organizations with a variety of topics ranging from clinical indications and challenges, future applications, ethics, regulatory issues, to EU grants and projects.

True to the innovative nature of the program, it also featured a new dedicated biotech stream to present the latest highlights from CAR-T innovators and biotech entrepreneurs, a patient forum, and a special session by the EBMT Trainee Committee and YoungEHA Ambassadors.
We received a record number of abstract submissions with more than 110 abstracts from CAR T-cell researchers in 18 countries on four continents. The three top-ranked abstracts were honored with the 2nd Emerging Investigator EHA & EBMT Cellular Immunotherapy Research Award.

In total the meeting attracted approximately 1,640 registrations (including faculty), of which over 1,100 attended the live days. All scientific sessions were recorded and made available on the platform, which remained open until March 12, 2022.

This meeting would not have been possible without the support from Kite-Gilead, Bristol Myers Squibb, Janssen Oncology, Novartis, Miltenyi Biotec and Miltenyi Biomedicine.

EHA-SWG SCIENTIFIC MEETING ON PEDIATRIC HEMATOLOGY 2022

April 7-9, 2022 | Virtual

Chairs: Prof A Iolascon (SWG on Red Cell and Iron), Prof C Balduini (SWG on Thrombocytopenias and Platelet Function Disorders), Prof C Dufour (SWG on Granulocyte and Constitutional Marrow Failure Syndromes), Prof D Prati (SWG on Tranfusion), Prof A Falanga (SWG on Bleeding and Thrombosis)

The main goal of the meeting was to improve the knowledge of participants on how to diagnose and treat inherited conditions in pediatric patients. During the meeting there were plenty of opportunities for the delegates to network and for one-on-one discussions with experts during the Welcome Ceremony, the Meet the Chairmen session, and during the coffee and lunch breaks.

The meeting included the following topics:

- Bone marrow failures syndromes
- Hemopoietic stem cell transplantation
- Consultative pediatric hematology
- Red cell disorders
- Gene therapy and gene editing
- Bleeding and coagulation disorders

Sessions were livestreamed directly on the virtual platform, enabling attendees from the world, including China, Turkey, Croatia, and Malaysia, to join. 184 participants (both virtual and in-person) from over 40 countries/regions attended. The average rating of the meeting by delegates was a 9.2/10.
Sessions were livestreamed directly in the virtual platform, facilitating attendees from countries across the world. The meeting was attended by 184 participants (both virtual and physical) from over 40 countries/regions. The average rating of the meeting that was given by delegates was a 9.2/10.

“My colleagues and I were really pleased to have access to this meeting because it was really useful for us as we work in molecular biology at a pediatric hospital in Argentina.”
– Anonymous delegate

EHA-SWG SCIENTIFIC MEETING “DEVELOPING A RESEARCH AGENDA FOR TRANSFUSION IN EUROPE”

September 15-17, 2022 | Hybrid

Chairs: S Stanworth and H Feys

The EHA-SWG Scientific Meeting “Developing a research agenda for transfusion in Europe” was led by S Stanworth and H Feys, with the main goal of fostering and developing networks of research for transfusion in Europe.

To give attendees a preview and let them know what to expect, the first a virtual ‘teaser’ was held on March 29, 2022. Attended by 330+ delegates, this 90-minute meeting addressed hot topics in the field of transfusion and initiated the creation of a roadmap for the next 5-10 years.

In September, attendees from various countries across Europe joined the main meeting, albeit in a smaller and more personalized setting. This meant everyone present had the opportunity to learn, discuss, and network. The meeting not only touched on elements of transfusion in hematology, but also helped early-career attendees with grant applications, gave patient perspectives, and offered oral and poster abstract presentations.

The meeting was attended by 55 participants (both virtual and physical). The average rating of the meeting given by delegates was 9.2/10.

Delegate: "The meeting taught us that progress starts by joining forces and sharing ideas. We hope that researchers in 5 years will say that the first seed of their cooperation was planted here at the EHA-SWG Meeting in Prague."

For younger researchers, Isabelle Verbaeys, a patient representative, pointed out the necessity of a patient-centered approach during the treatment of diseases and blood transfusion which was welcomed by participants of the meeting.
The meeting was attended by 55 participants (virtual and in-person). The average rating of the meeting given by delegates was a 9.2/10.

“The meeting taught us that progress starts by joining forces and sharing ideas. We hope that researchers in 5 years will say that the first seed of their cooperation was planted here at the EHA-SWG Meeting in Prague.” – Anonymous delegate

EHA-SWG SCIENTIFIC MEETING ON INTEGRATED CELL TRACKING IN ONCOHEMATOLOGY: DIAGNOSIS, TARGETED THERAPY AND RESIDUAL DISEASE

November 10-11, 2022 | Bordeaux, France, Hybrid

Meeting Chairs: MC Béné, Nantes University; G Zini, Università Cattolica S.Cuore - Fondazione Policlinico Gemelli-IRCCS

On November 10-12, meeting chairs Profs MC Béné and G Zini were joined by leading experts to present the state-of-the-art and future directions in laboratory and clinical oncohematology. The program contained a mixture of expert lectures, patient input and presentations from submitted abstracts.

On Thursday, November 10, the day started with new approaches for the diagnosis of hematological malignancies. Insight was provided on how new parameters on the hematology analyzers allow to suspect myelodysplastic and myeloproliferative syndromes. Morphology requires deep knowledge and remains prone to heuristic errors. In recent years and more likely in the future, digital morphology will help to fix knowledge errors and heuristics and improve patient management. This part was highlighted by numerous examples from Profs. M Eveillard, J Bentham, G Zini and T Haferlach.

The second day targeted clinical practitioners and the diagnostic of oncohematological diseases in practice. On the third day, four different conditions were discussed including myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, mastocytosis and related conditions, and follow up in multiple myeloma patients

Selected oral presentations
A selection of abstracts were eligible for acceptance during the meeting, the presentation format was in the form of oral presentations or poster presentations. In total, the program included ten oral presentations and three poster presentations.
In April 2022, the EHA Board agreed to stimulate engagement with Specialized Working Groups (SWGs) and provide financial support to small, SWG-initiated research projects.

This agreement led to the launch of three new SWG Grants of 20,000 euros designed to support projects that benefit network collaboration and increase engagement within these specialised groups.

Criteria for the grant application were:

- Non-interventional studies, like retrospective studies or prospective data collection are eligible for support.
- For “basic research” SWG-initiated projects, EHA will favor projects that leverage the collaborative nature of the SWG network and the mutual exchange of expertise.
- EHA encourages the submission of proposals involving junior members and partners from underrepresented countries to increase diversity and inclusion and support researchers.

These grants are designed to support costs such as data management, data analysis, sample collections, and storage. It does not support fellowships or pay for individual salaries, nor for the purchase of substantial equipment.

The call was opened during November-December 2022 to all SWGs to develop their ideas and apply for a research grant. We received nine different applications from 6 SWGs:

- SWG on Red Cells and Iron (1 application)
- SWG on AML (1 application)
- SWG Lymphoma Group (4 applications)
- SWG on Thrombocytopenias and Platelet Function Disorders (1 application)
- SWG CML & Aging in Hematology (1 collaborative application)
- SWG on Precision Hematology (1 application)

The SWG Committee assessed the applications based on the importance of the topic for further research, other sources of support already available for this proposal, and an explanation of the budget needs, as well as the general comments on the application.

After careful consideration and discussion, the SWG Committee chose three winners:

- SWG on AML: “Evaluation of the prognostic impact of subclonal FLT3-ITD mutations in acute myeloid leukemia: a retrospective multicenter study on behalf of the EHA AML-SWG” - Professor Maria Teresa Voso and Dr. Carmelo Gurnari
- SWG on Precision Hematology: “Standards for Functional Precision Medicine (StFPM)” - Professor Philipp Staber

Contracts will be signed with winners in 2023 to support their research ideas.
EHA AND NATIONAL SOCIETIES

Following the EHA National Societies Day in 2020, one of EHA’s priorities has been to intensify its relationships with national societies. These meetings are designed to connect national society presidents with the EHA Board to discuss important topics and see how we can work together for the benefit of hematologists.

In 2022, a dedicated Community team was created to help drive these discussions, strengthen collaboration with each national society, and create opportunities for hematologists in Europe. Following two years of COVID, the EHA2022 Congress in Vienna was the first opportunity to meet face to face. EHA hosted a networking dinner with conversations on topics such as guidelines, education, EU Affairs, and diversity, equity, and inclusion. 21 national society presidents or representatives of the board attended.

In September 2022, EHA was present at the annual meeting of the SIE (Italian Society of Hematology) as an exhibitor and connected with attendees.

During the EHA Balkan Day on November 10, 2022, national society representatives from Greece, Kosovo, Romania, Serbia, Türkiye, Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Montenegro, North Macedonia, and Slovenia came together to strengthen collaboration in the Balkan Region and share best practices.

EHA also sent European speakers to different national society meetings around the world to take part in joint symposia and share knowledge with the following partner societies:

- [VIRTUAL] European Society for Blood and Marrow Transplantation Annual Meeting
- [VIRTUAL] Korean Society of Hematology International Meeting
- [VIRTUAL] Hematology Society of Taiwan Annual Congress
- [VIRTUAL] British Society of Haematology Congress
- [HYBRID] Polish Society of Hematology and Transfusion Medicine (PTHiT)
- [HYBRID] Japanese Society of Hematology Annual Congress
- [VIRTUAL] European Association for Nuclear Medicine Annual Meeting
- [HYBRID] National Congress of the Spanish Hematology and Hemotherapy Society (SEHH), and National Congress of the Spanish Society of Thrombosis and Hemostasis (SETH)
- [HYBRID] Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Annual Congress
- [HYBRID] Turkish Society of Hematology Congress
- [VIRTUAL] Chinese Hematology Society Congress
- [HYBRID] Romanian Society of Hematology Congress
Young National Society Ambassadors (YNSA)

In 2020, EHA reached out to national societies in Europe to look at ways to better work with young hematologists in each country. This was the beginning of our ambassador program, where each national society appoints a young hematologist to the YNSA group to collaborate on projects, network with peers from across Europe, and improve the inclusion of young hematologists.

One project carried out in 2022 was a career mapping task force, created to gain insight into the career paths to become a hematologist in different countries. Mapping the career paths supports EHA in our advocacy priorities such as the Madrid Declaration and helps in harmonizing the education and training of hematologists, opening new paths for doctors, researchers, and patients.

These Young Ambassadors are now an integrated part of various activities, including the EHA2022 National Societies Presidents’ Dinner. 21 YNSA joined this dinner on behalf of their national society. They shared their ideas and needs with the different EHA Board members and connected with the other YNSA.

We currently have 35 early career representatives from 34 countries.

EHA Patient Advocacy Committee

EHA has a long-standing commitment to patient advocacy and established the EHA Patient Advocacy Committee (PAC) in June 2022. This committee consists of fourteen different umbrella patient organizations committed to improving the lives of patients with hematological disorders. This committee is a vital part of the European Hematology Association (EHA), working to bridge the gap between patients and healthcare providers, and advocating for patients’ needs on a local and global level.

One of the key roles of the PAC is to provide input and feedback on EHA initiatives, programs, and policies. This feedback helps to ensure that the needs of patients are taken into account and that EHA activities are aligned with patient needs and priorities.
In 2022, the Young EHA Community continued to grow and reached 2,196 members, making up 40% of our total membership. This means the role of the Young EHA committee is more important than ever.
After operating virtually for two years, meeting each other in person was once again possible at the Young EHA Research Meeting (YERM) 2022. Originally, intended as a smaller event focused on basic science, the meeting has now become a fully integrated part of the EHA Congress program. In 2022, YERM attracted over 520 attendees (virtual and physical) during its five sessions. Additionally, the committee organized two well-attended sessions at EHA2022.

In 2022, the YoungEHA (YEHA) Community continued to grow and reached 2,490 members. This means the role of the YEHA committee is more important than ever.
The YEHA Community ended the Congress with the EHA Grooves social event that attracted a large crowd that spent the evening bowling and networking.

**YOUNG EHA – STAYING IN TOUCH**

The number of Young EHA Twitter followers increased to 2,094, an increase of almost 600, thanks to the efforts of dedicated committee members.

The following was the tweet with the most impressions, engagement, and likes:

YoungEHA
@young_eha

This #EHA2022 we have meet in person (in some cases for the first time!) after two years working online👏

We hope you've enjoyed the conference and the #YoungEHA sessions😊

Wish everyone a safe trip back home & keep in touch with us!

@EHA Hematology
The EHA2022 Hybrid Congress was once more a success. Thanks to the great collaboration and support of the Scientific Program Committee and the EHA Board, the EHA2022 Hybrid Congress saw hematologists from around the world to immerse themselves in the latest news in hematology and its subspecialties. This success would not have been the same without the support of EHA’s industry partners and sponsors; and last, but not least, without the passion and enthusiasm of members of the hematology community. The EHA2022 Congress chapter closed on August 15, 2022. You will find the EHA2022 Congress report below.

EHA is working on the next Congress, innovating the congress model further.
EHA2022
HYBRID  JUNE 9-17  VIENNA

27th Annual Congress of EHA | June 9-17, 2022
Platform close | August 15, 2022

EHA2022: your gateway to hematology.

16,999
REGISTRATIONS

10,550
HYBRID REGISTRATIONS

5,889
VIRTUAL REGISTRATIONS

555
VIENNA ONLY

6
CONTINENTS

122
COUNTRIES

41 EU + 81 NON-EU

TOP10
COUNTRIES WITH THE MOST REGISTRANTS

United States
United Kingdom
Germany
France
Italy
Spain
Switzerland
the Netherlands
Austria
China
43% of invited speakers / chairs were women.

2,358 abstracts were submitted.

47 late-breaking abstracts were submitted.

35 countries participated in the invited speaker program.

24 EU + 11 non-EU

TOP10 countries with the most abstract submissions:
- United States
- China
- United Kingdom
- Italy
- Spain
- Germany
- Russia
- the Netherlands
- India
- France

15,312,405 reached on Facebook & Twitter

20,565,214 impressions on Facebook & Twitter
HARMONIZING AND BUILDING KNOWLEDGE
EDUCATION

“AN INVESTMENT IN KNOWLEDGE PAYS THE BEST INTEREST”

EHA CAMPUS

In 2022, the EHA Campus offered numerous high-quality courses, many of which were developed by our team of hematology experts, instructional design specialists, and medical writers. By producing our own courses, EHA ensures unbiased content that is not influenced by commercial interests. Moreover, we can frequently update the material as scientific knowledge advances.

The EHA Campus is continuously broadening its coverage of EHA Curriculum topics. In 2022, we introduced new programs, courses, podcasts, and clinical cases that cover an increasing number of European Hematology Curriculum areas. We have also introduced new course formats, including flashcards and algorithms, in order to offer a variety of educational opportunities for our members. Finally, we regularly publish different formats of social media learning content, ensuring that EHA reaches the widest possible audience with content for everyone.

WHAT DO OUR MEMBERS SAY?

4.5/5

AVERAGE RATING BY EHA CAMPUS PARTICIPANTS

97%

WOULDN’T ENGAGE IN SIMILAR COURSES

98%

WOULD RECOMMEND COURSES TO COLLEAGUES
LOGINS PER MONTH

2021: 1581
2022: 2412

AVERAGE UNIQUE USERS/ VISITORS PER MONTH

2021: 367
2022: 436

COURSE ENROLMENTS PER MONTH

2021: 343
2022: 467

COURSES COMPLETED BY PARTICIPANTS (PASS PERCENTAGE)

2021: 48%
2022: 42%

Courses completed in 2022: 2359
Course enrolments in 2022: 5603
Campus users/visitors in 2022: 5237
Total logins in 2022: 27939
QR CASES:

QR Case 6: Mantle Cell Lymphoma
QR Case 7: Mantle Cell Lymphoma (2)
QR Case 8: DLBCL
QR Case 9: CAR-T
QR Case 10: CML (2)
QR Case 11: MPN
QR Case 12: Managing Pregnancy in MPN
QR Case 13: Tranfusion in MM
QR Case 14: Aplastic Bone Marrow
QR Case 15: Aplastic Anemia
QR Case 16: Christmas Disease

COURSES

Autoimmune Neutropenia
Mycosis Fungoides and Sézary Syndrome (CTCL)
Gene Therapy in Hemoglobinopathies
The Divided Brain: Emotion vs. Logic in Patient Communication
EHA Unplugged - Cutaneous T Cell Lymphoma (CTCL)

NEW FORMATS: FLASHCARDS AND ALGORITHMS

MDS Flashcards
CML Flashcards
Iron Deficiency Diagnosis Algorithm
NEW PROGRAMS

- Chronic Lymphocytic Leukemia
  - The Basis of Lympho-hematopoiesis
  - Diagnosis and Clinical Presentation of CLL
  - Chronic Lymphocytic Leukemia Pathophysiology
  - Chronic Lymphocytic Leukemia Treatment
- Multiple Myeloma
  - Diagnosis and Clinical Presentation of MM
  - Multiple Myeloma Molecular Genetics
  - Multiple Myeloma Treatment
- Gene Therapy Techniques
  - Overview of Cell and Gene Therapies
- Myeloproliferative Neoplasms
  - Polycythemia Vera
- How to Read a Paper
  - How to Read a Paper: Basics of Scientific Literature
  - How to Read a Paper: Critical Appraisal of Clinical Research
- Castleman Disease

NEW COURSES IN EXISTING PROGRAMS

- EHA-LSHBT Hematology Updates
  - Hematology Updates - Bleeding Disorders
  - Hematology Updates - Multiple Myeloma
  - Hematology Updates - Sickle Cell Disease (SCD)
- Diagnosing and treating iron deficiency
  - Iron Deficiency: Inflammatory Bowel Disease
  - Iron Deficiency: Oncology
  - Iron Deficiency: Perioperative
- Hematology of the Aging Patient: Dispelling Myths (each course includes an e-learning module and a podcast)
  - Patient-Reported Outcomes (PROs) in Older Adults
In 2022, EHA published 27 podcasts. We expanded the scope of our podcasts to include subjects outside the EHA Hematology Curriculum. They include podcasts on EHA and the war in Ukraine, Health Technology Assessment (HTA), and Plan S. The content for podcasts was obtained from interviews with experts, EHA2022 spotlight talks, and clinical cases written by experts.

### TOTAL DOWNLOADS (LISTENS)

5561

### AVERAGE DOWNLOADS (LISTENS) PER MONTH

618

### HIGHEST DOWNLOADS (LISTENS) PER EPISODE

510

We have listeners from 100 countries. The United Kingdom has the highest percentage of downloads at 19.7%, followed by Australia (10.7%), and the United States (9.1%). Almost our entire online audience (92.4%) accesses our podcasts via mobile apps, the rest use desktop apps or browsers. Most of our podcasts are accessed from Apple Podcasts and Spotify.

<table>
<thead>
<tr>
<th>Country</th>
<th>Downloads</th>
<th>Country</th>
<th>Downloads</th>
</tr>
</thead>
<tbody>
<tr>
<td>United Kingdom</td>
<td>205 (19.7%)</td>
<td>Australia</td>
<td>111 (10.7%)</td>
</tr>
<tr>
<td>Australia</td>
<td>111 (10.7%)</td>
<td>United States</td>
<td>95 (9.1%)</td>
</tr>
<tr>
<td>United States</td>
<td>95 (9.1%)</td>
<td>Italy</td>
<td>65 (6.3%)</td>
</tr>
<tr>
<td>Italy</td>
<td>65 (6.3%)</td>
<td>Spain</td>
<td>54 (5.2%)</td>
</tr>
<tr>
<td>Spain</td>
<td>54 (5.2%)</td>
<td>Germany</td>
<td>36 (3.5%)</td>
</tr>
<tr>
<td>Germany</td>
<td>36 (3.5%)</td>
<td>Denmark</td>
<td>29 (2.8%)</td>
</tr>
<tr>
<td>Denmark</td>
<td>29 (2.8%)</td>
<td>Belgium</td>
<td>28 (2.7%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Platform</th>
<th>Downloads</th>
<th>Platform</th>
<th>Downloads</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apple podcast</td>
<td>577 (55.5%)</td>
<td>Spotify</td>
<td>350 (33.7%)</td>
</tr>
<tr>
<td>Spotify</td>
<td>350 (33.7%)</td>
<td>Unknown</td>
<td>21 (2.0%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>21 (2.0%)</td>
<td>Pocket Casts</td>
<td>18 (1.7%)</td>
</tr>
<tr>
<td>Pocket Casts</td>
<td>18 (1.7%)</td>
<td>Overcasts</td>
<td>16 (1.5%)</td>
</tr>
<tr>
<td>Overcasts</td>
<td>16 (1.5%)</td>
<td>Chrome</td>
<td>11 (1.1%)</td>
</tr>
<tr>
<td>Chrome</td>
<td>11 (1.1%)</td>
<td>Google Podcasts</td>
<td>11 (1.1%)</td>
</tr>
<tr>
<td>Google Podcasts</td>
<td>11 (1.1%)</td>
<td>PodcastAddict</td>
<td>10 (1.0%)</td>
</tr>
</tbody>
</table>
In 2022, we set up four microlearning programs: LearningMondays, EHAcase, ThinkingThursday, and QRCases. In 2022, we defined a standard format, redesigned the look of our microlearning posts, and expanded them to four social media platforms: LinkedIn, Twitter, Instagram, and Facebook.

**LearningMondays (LM)**

On alternate Mondays, you will find a hematological challenge to test your knowledge. LM exists in two forms: a mailing and social media (SM) posts. LM consists of clinical cases with a question to test your hematology knowledge. In the first post, we provide the question and in the second post we provide the answer and an explanation. The content for LM is obtained from experts and past EHA Exam questions.

In 2022, a total of 24 Learning Monday challenges were posted.

The average numbers per post in 2022 according to social media platform is shown in the table to the right.

**EHA Cases**

On alternate Mondays, we challenge our readers with bite-size clinical cases and morphology challenges. EHA Cases are available on LinkedIn and Twitter. In 2022, we published a total of 25 EHA Cases.

The average numbers per post in 2022 according to social media platform is shown in the table to the right.

**Average Numbers Per LearningMondays Post**

<table>
<thead>
<tr>
<th></th>
<th>Likes/Reactions</th>
<th>Appearances on profiles</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Facebook</td>
<td>22</td>
<td>1867</td>
<td>13</td>
</tr>
<tr>
<td>LinkedIn</td>
<td>28</td>
<td>2310</td>
<td>11</td>
</tr>
<tr>
<td>Twitter</td>
<td>104</td>
<td>4794</td>
<td>8</td>
</tr>
<tr>
<td><strong>AVERAGE</strong></td>
<td><strong>70</strong></td>
<td><strong>3552</strong></td>
<td><strong>10</strong></td>
</tr>
</tbody>
</table>

**Average Numbers Per EHA Case Post**

<table>
<thead>
<tr>
<th></th>
<th>Likes/Reactions</th>
<th>Appearances on profiles</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Facebook</td>
<td>22</td>
<td>1867</td>
<td>13</td>
</tr>
<tr>
<td>LinkedIn</td>
<td>28</td>
<td>2310</td>
<td>11</td>
</tr>
<tr>
<td><strong>AVERAGE</strong></td>
<td><strong>70</strong></td>
<td><strong>3552</strong></td>
<td><strong>10</strong></td>
</tr>
</tbody>
</table>

LM and EHA cases are an effective alternative way of training hematologists. Questions and clinical cases are taken from past exams and obtained from experts. These questions and challenges can be thought of as a form of training and preparation for the EHA hematology exam.
Thinking Thursday

Visual challenges proposed to our readers every other Thursday on Twitter, Instagram, LinkedIn, and Facebook. We offer schemas depicting clinical challenges with missing information that the readers must guess. In 2022, we published a total of 29 Thinking Thursday schemas.

AVERAGE NUMBERS PER THINKINGTHURSDAY POST

<table>
<thead>
<tr>
<th>Likes/Reactions</th>
<th>Appearances on profiles</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Facebook</td>
<td>44</td>
<td>2953</td>
</tr>
<tr>
<td>LinkedIn</td>
<td>74</td>
<td>4057</td>
</tr>
<tr>
<td>Twitter</td>
<td>120</td>
<td>4701</td>
</tr>
<tr>
<td>AVERAGE</td>
<td>93</td>
<td>3740</td>
</tr>
</tbody>
</table>

QR Cases

Extended clinical cases in a bite-size format. In QR Cases, we introduce interactive clinical cases and clinical algorithms to educate on diagnostic criteria, treatment guidelines, and management of hematological disorders. QR cases are published monthly and accessed on your phone by scanning the QR code provided. In 2022, we published 12 QR cases.

VIEWED/ENROLLED

2932

COMPLETIONS (AVG):

50%

RATING

4.7/5

All of our Social Media Learning posts can be found here: [https://linktr.ee/EHAEducation](https://linktr.ee/EHAEducation)
The sixth European Hematology Exam took place on June 10, 2022. EHA was pleased to welcome 58 candidates to the main session at the EHA Congress in Vienna, Austria. Additionally, national hematology societies were offered the chance to organize a session for candidates residing in their countries; parallel local exam sessions were held in 11 countries. The exam consists of 100 multiple choice questions testing the candidates' knowledge on all eight sections of the European Hematology Curriculum. In total, 166 candidates took the exam simultaneously at 12 locations. 138 candidates (83%) passed the exam this year. Read the full report here.

**TABLE 1: NUMBER OF CANDIDATES, PER LOCATION (EXAM LOCATION IS COUNTRY OF RESIDENCE)**

<table>
<thead>
<tr>
<th>Parallel exam location</th>
<th>Number of candidates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albania</td>
<td>1</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>3</td>
</tr>
<tr>
<td>Egypt</td>
<td>9</td>
</tr>
<tr>
<td>Estonia</td>
<td>2</td>
</tr>
<tr>
<td>Finland</td>
<td>2</td>
</tr>
<tr>
<td>Greece</td>
<td>10</td>
</tr>
<tr>
<td>Iraq</td>
<td>27</td>
</tr>
<tr>
<td>Portugal</td>
<td>5</td>
</tr>
<tr>
<td>Spain</td>
<td>22</td>
</tr>
<tr>
<td>Switzerland</td>
<td>15</td>
</tr>
<tr>
<td>Türkiye</td>
<td>12</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>108</strong></td>
</tr>
</tbody>
</table>

**TABLE 2: COUNTRY OF RESIDENCE OF CANDIDATES WHO TOOK EXAM AT MAIN SESSION (EHA CONGRESS IN VIENNA)**

<table>
<thead>
<tr>
<th>Candidate Country of residence</th>
<th>Number of candidates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>3</td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>2</td>
</tr>
<tr>
<td>Bahrain</td>
<td>1</td>
</tr>
<tr>
<td>Belgium</td>
<td>1</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>5</td>
</tr>
<tr>
<td>Estonia</td>
<td>1</td>
</tr>
<tr>
<td>Germany</td>
<td>1</td>
</tr>
<tr>
<td>Greece</td>
<td>3</td>
</tr>
<tr>
<td>India</td>
<td>1</td>
</tr>
<tr>
<td>Netherlands</td>
<td>1</td>
</tr>
<tr>
<td>Pakistan</td>
<td>1</td>
</tr>
<tr>
<td>Paraguay</td>
<td>1</td>
</tr>
<tr>
<td>Portugal</td>
<td>13</td>
</tr>
<tr>
<td>Qatar</td>
<td>2</td>
</tr>
<tr>
<td>Romania</td>
<td>2</td>
</tr>
<tr>
<td>Slovenia</td>
<td>1</td>
</tr>
<tr>
<td>Spain</td>
<td>8</td>
</tr>
<tr>
<td>Switzerland</td>
<td>1</td>
</tr>
<tr>
<td>Tunisia</td>
<td>1</td>
</tr>
<tr>
<td>Türkiye</td>
<td>4</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>4</td>
</tr>
<tr>
<td>United States</td>
<td>1</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>58</strong></td>
</tr>
</tbody>
</table>

**CAREER PHASE OF 2022 EXAM CANDIDATES:**

- 67% Currently in specialty training
- 16% Completed training <5 years ago
- 11% Completed training 5-10 years ago
- 6% Completed training >10 years ago

PAGE 73
EUROPEAN HEMATOLOGY PROGRESS TEST

The European Hematology Progress Test, an online learning tool available to EHA members only, is designed to:
- Help EHA members identify their knowledge gaps in hematology
- Keep track of their improvements over time
- Prepare for the European Hematology Exams.

The test is modelled on previous European Hematology Exams and is available to participants for one full month in March and November.

Upon completion of the test, participants receive immediate feedback on their answers, including references for more in-depth reading and studying. A few weeks after the test’s closure, they receive the comprehensive results per curriculum section, together with feedback on their overall performance and progress.

The number of participants in the progress test is growing steadily. Since the first intake, the number of participants has doubled.
- March 2022: 240 members completed the test,
- November 2022: 199 members completed the test,
- 20% of the participants took the test twice in 2022.

The countries where the progress test is more successful are:
- Spain,
- Switzerland,
- UK,
- Portugal.

According to the participant surveys, the reasons for taking the progress test are to:
- use it as a learning tool
- measure their knowledge on each section of the curriculum
- prepare for the EHA Exam.

The European Hematology Progress Test is a valuable learning tool for EHA members. Its popularity is growing, and it enables the EHA community to track their progress over time.
<table>
<thead>
<tr>
<th>Country</th>
<th>Completions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spain</td>
<td>54</td>
</tr>
<tr>
<td>Switzerland</td>
<td>37</td>
</tr>
<tr>
<td>Portugal</td>
<td>33</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>31</td>
</tr>
<tr>
<td>Netherlands</td>
<td>28</td>
</tr>
<tr>
<td>Greece</td>
<td>25</td>
</tr>
<tr>
<td>Italy</td>
<td>16</td>
</tr>
<tr>
<td>Germany</td>
<td>15</td>
</tr>
<tr>
<td>Türkiye</td>
<td>14</td>
</tr>
<tr>
<td>India</td>
<td>14</td>
</tr>
<tr>
<td>Sweden</td>
<td>12</td>
</tr>
<tr>
<td>Romania</td>
<td>11</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>11</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>10</td>
</tr>
<tr>
<td>United States of America</td>
<td>9</td>
</tr>
<tr>
<td>Belgium</td>
<td>9</td>
</tr>
<tr>
<td>Estonia</td>
<td>8</td>
</tr>
<tr>
<td>Poland</td>
<td>8</td>
</tr>
<tr>
<td>Egypt</td>
<td>8</td>
</tr>
<tr>
<td>Australia</td>
<td>8</td>
</tr>
<tr>
<td>Austria</td>
<td>7</td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>6</td>
</tr>
<tr>
<td>Mexico</td>
<td>6</td>
</tr>
<tr>
<td>France</td>
<td>5</td>
</tr>
<tr>
<td>Brazil</td>
<td>5</td>
</tr>
<tr>
<td>Iraq</td>
<td>5</td>
</tr>
<tr>
<td>Hungary</td>
<td>5</td>
</tr>
<tr>
<td>Ireland</td>
<td>5</td>
</tr>
<tr>
<td>Malaysia</td>
<td>4</td>
</tr>
<tr>
<td>Pakistan</td>
<td>4</td>
</tr>
</tbody>
</table>

...  

**GRAND TOTAL** 464
THE EHA MASTER CLASS IS GROWING

The 2022/23 EHA Master Class welcomed a diverse group of 90 mentees from 34 countries and 16 mentors from 11 countries. This marked a 64% increase in the number of mentees compared to the 2021/22 Master Class. The EHA Master Class is an online clinical preceptorship that allows participants to work in groups with a mentor and study five complex hematology clinical cases in depth over a period of nine months. Each case is written by an EHA expert and mentors are selected because of their established expertise in various fields of hematology.

The following medical cases were studied: acute myeloid leukemia, sickle cell disease, transfusion, lymphoma, and antiphospholipid syndrome. Here you can read the editorial published in HemaSphere: "The Renovated Face of EHA Classical Master Class: A Survey-based Evaluation on Behalf of the EHA Campus Working Group".

MASTER CLASS 22-23: PARTICIPANTS COUNTRY OF ORIGIN

<table>
<thead>
<tr>
<th>COUNTRIES</th>
<th>PARTICIPANTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Turkey</td>
<td>17</td>
</tr>
<tr>
<td>Portugal</td>
<td>8</td>
</tr>
<tr>
<td>Greece</td>
<td>7</td>
</tr>
<tr>
<td>Romania</td>
<td>6</td>
</tr>
<tr>
<td>Italy</td>
<td>5</td>
</tr>
<tr>
<td>Egypt</td>
<td>4</td>
</tr>
<tr>
<td>Brazil</td>
<td>4</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>3</td>
</tr>
<tr>
<td>Armenia</td>
<td>3</td>
</tr>
<tr>
<td>Switzerland</td>
<td>2</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>2</td>
</tr>
<tr>
<td>Poland</td>
<td>2</td>
</tr>
<tr>
<td>India</td>
<td>2</td>
</tr>
<tr>
<td>Spain</td>
<td>2</td>
</tr>
<tr>
<td>Uruguay</td>
<td>2</td>
</tr>
<tr>
<td>Pakistan</td>
<td>2</td>
</tr>
<tr>
<td>Denmark</td>
<td>2</td>
</tr>
<tr>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td><strong>GRAND TOTAL</strong></td>
<td><strong>90</strong></td>
</tr>
</tbody>
</table>
## MASTER CLASS 2021-2022 SURVEY RESULTS
### CASES STUDIES

<table>
<thead>
<tr>
<th>AGE</th>
<th>COUNTRY</th>
<th>AML</th>
<th>SCD</th>
<th>TRANSFUSION</th>
<th>LYM-PHOMA</th>
<th>ANTI-PHOSPHOLIPID</th>
<th>COORDINATION BY EHA STAFF</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>India</td>
<td>4</td>
<td>4</td>
<td>5</td>
<td>4</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>42</td>
<td>Egypt</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>45</td>
<td>India</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>55</td>
<td>UK</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>36</td>
<td>Greece</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>33</td>
<td>Italy</td>
<td>5</td>
<td>5</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>33</td>
<td>USA</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>40</td>
<td>Iraq</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>30+</td>
<td>India</td>
<td>4</td>
<td>4</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>32</td>
<td>Portugal</td>
<td>5</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>41</td>
<td>Sweden</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>29</td>
<td>Portugal</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>34</td>
<td>Türkiye</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>37</td>
<td>Switzerland</td>
<td>5</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>35</td>
<td>Bangladesh</td>
<td>2</td>
<td>3</td>
<td>5</td>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>33</td>
<td>Brazil</td>
<td>4</td>
<td>3</td>
<td>5</td>
<td>4</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>36</td>
<td>Portugal</td>
<td>4</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>29</td>
<td>Estonia</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>3</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>38</td>
<td>Turkey</td>
<td>4</td>
<td>4</td>
<td>1</td>
<td>4</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>44</td>
<td>Bahrain</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>32</td>
<td>Portugal</td>
<td>5</td>
<td>5</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>41</td>
<td>Egypt</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>34</td>
<td>Bangladesh</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>3</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>59</td>
<td>Saudi Arabia</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>4</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>31</td>
<td>Portugal</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>31</td>
<td>Portugal</td>
<td>5</td>
<td>5</td>
<td>4</td>
<td>5</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>44</td>
<td>Switzerland</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>4</td>
</tr>
</tbody>
</table>

**AVERAGE** 3.7 3.5 3.8 3.5 3.6 4.72
LIGHTING THE FLAME

The Lighting the Flame program was launched in 2022 with the aim of providing mentorship and guidance to medical students, residents, and interns to help them become familiar with hematology as clinicians and/or researchers.

The program, divided into three phases, aims to provide prospective hematologists with a clearer idea of what hematology entails from a practical point of view and get a head-start in the field.

A wide range of content designed to introduce the field is hosted on the Lighting the Flame campus: QR cases, interviews, podcasts, and materials related to a specific diseases such as thalassemia or iron deficiency. As of now, over 350 individuals have enrolled in our campus with the aim of gaining a deeper understanding of hematology.

GEOGRAPHICAL BREAKDOWN OF PARTICIPANTS

| 358 registered participants |

<table>
<thead>
<tr>
<th>Country</th>
<th>No. of Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Romania</td>
<td>26</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>23</td>
</tr>
<tr>
<td>Poland</td>
<td>21</td>
</tr>
<tr>
<td>Italy</td>
<td>19</td>
</tr>
<tr>
<td>India</td>
<td>17</td>
</tr>
<tr>
<td>Türkiye</td>
<td>15</td>
</tr>
<tr>
<td>Greece</td>
<td>14</td>
</tr>
<tr>
<td>Germany</td>
<td>14</td>
</tr>
<tr>
<td>Egypt</td>
<td>12</td>
</tr>
<tr>
<td>China</td>
<td>12</td>
</tr>
<tr>
<td>Portugal</td>
<td>11</td>
</tr>
<tr>
<td>Brazil</td>
<td>9</td>
</tr>
<tr>
<td>Netherlands</td>
<td>9</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>8</td>
</tr>
</tbody>
</table>

GEOGRAPHICAL BREAKDOWN OF PARTICIPANTS
INTERNATIONAL COLLABORATION & OUTREACH

INTERNATIONAL COLLABORATION

EHA’s International Collaboration Program in 2022 sent Europe-based speakers to countries around the world to take part in a variety of joint symposia, virtually and in-person, sharing their knowledge and providing education. The program is an important tool to facilitate connection between Europe and countries around the world.

These joint symposia were organized at the following (partner society) congresses:

- American Society of Hematology
- Azerbaijan Hematology Specialists Society
- Brazilian Society for Hematology, Hematherapy and Cellular Therapy
- British Society of Haematology
- Chinese Society of Hematology
- European Association for Nuclear Medicine
- European Society for Blood and Marrow Transplantation
- Hematology Society of Taiwan
- Indian Society of Haematology and Blood Transfusion
- International Society for Experimental Hematology
- International Symposium on Amyloidosis
- Italian Society on Hemostasis and Thrombosis
- Japanese Society of Hematology
- Korean Society of Hematology
- Philippine College of Hematology and Transfusion Medicine
- Polish Society of Haematology and Transfusion Medicine
- Portuguese Society of Hematology
- Romanian Society of Hematology
- Turkish Society of Hematology
GLOBAL OUTREACH PROGRAM

In 2022 EHA’s Global Outreach Program meant the return of in-person attendance for many meetings, though speaker participation remained a mix of virtual and in-person. Nonetheless, our aim remained unchanged: to provide hematology medical education to countries outside Europe based on local needs.

EHA’s Global Outreach Program consists of Hematology Tutorials, joint symposia and Highlights of Past EHA (HOPE) meetings. There is also the Joint Balkan Hematology Day.

HEMATOLOGY TUTORIALS

Hematology Tutorials are courses that provide laboratory and clinical hematologists with an integrated diagnostic and clinical work-up of hematological disorders. The scientific program takes participants through diagnostic and clinical pathways with plenary lectures, interactive clinical case study sessions, and self-assessment sessions. The faculty is available to provide individual guidance to participants throughout the meeting.

In 2022, EHA organized three tutorials, which were held either fully virtual, or in a hybrid format so local participants could attend in-person.

EHA-SLCH HEMATOLOGY TUTORIAL ON HEMATOLOGICAL DISORDERS

March 18-19, 2022 | Hybrid

Chairs: Prof G Gaidano, Dr A Weerawardena, and Dr C Wickramaratne

The tutorial was held in a hybrid format; live streamed from Colombo, Sri Lanka. The overarching topic of the meeting was hematological disorders, including infrequently discussed disorders such as hemophagocytic lymphohistiocytosis. The meeting consisted of eight sessions, featuring a lecture and self-assessment case given by a speaker from abroad, and a clinical case presented by a local speaker.

The tutorial was attended by 207 participants (both virtual and physical) from 29 countries, with more than half of the attendees from Sri Lanka. 95% of the participants rated the program as excellent.

A faculty member said: "A very instructive scientific event with an impact on clinical practice. It is the best way to interact with doctors who practice in countries with limited resources."
This year marked the 10th jointly-organized Hematology Tutorial with the Turkish Society of Hematology (TSH). These tutorials are held as part of the Turkish School of Hematology, a training program for Turkish fellows in hematology. This year, the program focused on bone marrow failure syndromes, with four sessions covering both diagnosis and treatment of various syndromes.

The 2022 virtual tutorial saw almost 50 unique viewers per session, which meant that most registrants joined each session. For the self-assessment cases, the polling numbers were lower than expected, but overall, the vast majority (92%) rated the meeting Good or Excellent.

Prof Ar, chair of the meeting and president of TSH said: “Thank you all on behalf of the Board of the Turkish Society of Hematology for your continuous support to facilitate the collaboration between our societies and for your contribution to our mission of countrywide standardisation of hematology education.”

The EHA-AAH Balkan Hematology Tutorial was a continuation of the virtual mini-tutorial held in collaboration with the Albanian Association of Hematology (AAH). The tutorial received 333 virtual registrations and 50 in-person registrations from Albania and Kosovo. The meeting focused on novel therapies in lymphomas.

The tutorial was the first meeting EHA held following COVID-19 restrictions. Therefore, the meeting converted from a virtual to a hybrid format to accommodate attendees from the area and international faculty.

Keynote speakers from across Europe joined attendees in Tirana, Albania while speakers from the region, proposed by the partner societies from the Balkans, joined virtually.

During the Q&A, participants could interact and have questions answered live by the faculty. The mini Tutorial was attended by more than 100 unique attendees from over 26 countries, including Armenia, Georgia, Italy, Moldova, United Kingdom, Bolivia, Saudi Arabia, and more.

With feedback such as “... an opportunity to discuss the ‘burning’ topics in my field of expertise” and “as a little nation and subsequently the low quantity of hematologists, I wholeheartedly believe, future internet based congresses (not just online) will be more productive for us, as far as discernment and educating”, we are able to look back at a successful mini Tutorial with AHA and GBMTA.
The HOPE program is intended for physicians, scientists, and medical students in Europe, Middle East and North Africa (MENA), Asia, and Latin America (LA) who could not attend the EHA Congress or who were interested in additional sessions and interaction with the speakers.

In 2022, the meeting programs were compiled by representatives from the EHA Global Outreach Program Committee and respective regional partners. Topics and speakers were selected from the EHA2022 Hybrid Congress program with a regional focus in mind and to facilitate new, unique sessions for each meeting.

HOPE Asia and HOPE LA were hybrid meetings while HOPE MENA was held fully virtually.

The three HOPE 2022 meetings were kindly supported by Janssen, whose EHA2022 sessions were also made available to registered participants via the platform.
HIGHLIGHTS OF PAST EHA (HOPE) ASIA 2022

September 2-3, 2022 | Bangkok, Thailand and Virtual

EHA, the Thai Society of Hematology (TSH), and the faculty members were joined by more than 75 hematologists in Bangkok and over 175 attendees virtually for the first hybrid HOPE meeting. After warm words of welcome from EHA and TSH, and an opening ceremony by TSH, the meeting began.

On the first day, attendees heard the presentations from the EHA2022 Hybrid Congress, focusing on lymphoid malignancies, acute leukemias, and red cell disorders & bone marrow failures. Additionally, Dr U Anurathapan and Dr A Taher gave exclusive HOPE Asia presentations on "Cellular Therapy in Pediatric Leukemias" and "Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management" respectively.

The second day commenced with a regional joint symposium: "thalassemia registry and regional perspectives". The session, with presentations from Thailand, Bangladesh, India, Malaysia, Pakistan, Philippines, and Sri Lanka, was one of the most valued sessions by attendees. The regional symposium was followed by sessions on multiple myeloma, myelodysplastic syndromes/myeloproliferative neoplasms, and thrombosis.

"I thought the session on the different regional countries’ registries was excellent and I learned a lot. I would love the opportunity to attend again in future" - HOPE Asia Faculty

The HOPE Asia partners played a significant role in identifying the local hematological needs of their respective country and region whilst composing the program.

In addition, the partners recommended talented and enthusiastic chairs for each session and a selection of great regional experts who gave their presentations in the regional joint symposium.
October 22, 2022 | Virtual
Chairs: Andres Ferreri (EHA) & Mohamad Qari (SSH)

This year’s HOPE MENA meeting was originally planned to take place in-person in Jeddah, Saudi Arabia but converted to a virtual format. The meeting was organized in collaboration with the Saudi Society of Hematology (SSH).

The meeting could be attended free of charge via the EHA platform and was aimed at participants from the Middle East & North Africa. A total of 225 registrations from 32 countries were attended the meeting.

The program included sessions on chronic lymphoproliferative disorders, myeloma, acute leukemia in adults, myeloid malignancies, lymphomas, and thrombosis and hemostasis. A regional joint symposium on sickle cell anemia and thalassemia was organized in collaboration with three partner societies from the region.

In total 89 unique participants joined the virtual meeting excluding the faculty.
This year, the HOPE LA meeting was held in collaboration with the Asociación Colombiana de Hematología y Oncología (ACHO) and linked to their annual congress. There were two parts to the program: oncology and hematology. HOPE provided the hematology program but remained open to all.

The meeting could be attended in-person in Colombia or virtually via the EHA or ACHO platforms. There were close to 350 attendees onsite and 170 virtual registrations, from 26 different countries, mainly in Latin America.

The regional symposium’s topic was 'The impact of COVID-19’. Each presenter was very open about the current situation and consequences of the pandemic in their respective countries. The honesty and was much appreciated and respected by attendees.

Another highly appreciated session was dedicated to Latin American Collaborative Groups. Representatives from GELAMM (Grupo Latinoamericano de estudio de Mieloma Múltiple), GLAM Grupo Latinoamericano de Síndromes Mielodisplásicos), LANET (LANet de Leucemia Mieloide Crónica) and GELL (Grupo LatinAmericano de Linfomas) presented their current work and future goals. The session "Information as a bridge for equity in health in Latin America” also looked towards the future focusing on how the use of AI can be beneficial in the hematology field.

The meeting would not have been possible without the invaluable input and participation by all the HOPE LA Partners.
The 3rd EHA-Balkan Hematology was organized in conjunction with the 33rd National Congress of the Hellenic Society of Hematology (HSH). Partner societies from the Balkan region were invited to participate in the program and meeting itself, and 10 partner societies agreed.

The program had 25 faculty members from 11 partner countries and focused on various types of lymphomas covering the following topics:

1. Chronic lymphocytic leukemia (CLL) and indolent lymphomas
2. Aggressive non-Hodgkin lymphomas
3. CAR T-cell therapies
4. Hodgkin lymphoma (HL)

A session on “Lighting the Flame & Regional Collaboration” was included in the program as the EHA initiative was also applicable to attendees of the meeting.

Attendance numbers were high and the level of activity on-site was strong with 515 in-person attendees and 271 virtual attendees. There were various physical meetings between the partner societies to discuss further collaboration between the different societies and future EHA-Balkan activities, such as tutorials and Balkan Hematology Days.
October 17-20, 2022 | Palermo, Italy
Topic: “Extrinsic signals and perturbations in normal and malignant hematopoiesis”

On October 17-20, 2022, the inaugural EHA Research Conference titled “Extrinsic signals and perturbations in normal and malignant hematopoiesis” was held in Palermo (Sicily), Italy.

The meeting focused on presenting, synthesizing, and discussing the state-of-the-art of extrinsic signalling to, and perturbation of normal and malignant hematopoietic stem cells. The meeting is positioned to become the premier scientific meeting of EHA. The intimate and research topic-focused nature of the meeting will greatly complement the much larger, wide-ranging and more clinically/translationally oriented EHA Annual Congress that takes place in June.

The meeting covered following topics:
- Aging hematopoietic stem cells (HSC): epigenomic regulation, inflammation, stem cell dynamics
- The role of inflammation in HSC regulation
- Epigenetic mechanisms regulating normal and malignant HSC
- The bone marrow microenvironment under inflammatory stress
- Metabolic regulation of normal and malignant HSC
- Extracellular factors regulating HSC in normal and malignant conditions

There were 126 abstracts submitted to the conference, of which 125 were accepted. 12 of these abstracts were selected for an oral presentation integrated into the program. The remaining abstracts were invited for a poster presentation during the two extended poster sessions. There were 25 faculty members from Europe and over 140 delegates present during the meeting.

The meeting was received well, mostly due to the buzzing atmosphere of the meeting and the well-received thematic sessions that were relevant to their work (93% found the conference very relevant to their work). The conference was rated a 9 out of 10 by the attendees. EHA would like to thank the meeting chairs, faculty, and delegates for their valuable input and participation in making the first EHA Research Conference successful. The foundation has been laid for the EHA Research Conference to grow and improve in 2024 and beyond.
LAUNCH OF INITIATIVES TO LEARN AND ENGAGE WITH CAR T-CELL PATIENTS

Two major initiatives stand out in a year in which T2EVOLVE’s eight work packages progressed with their work: the launches of the patient hub and the European Patient Survey on CAR T-cell therapy.

The patient hub offers a one-stop-shop to CAR T-cell patients looking for information. The hub has been carefully curated by the T2EVOLVE consortium. It features information from its diverse group of partners ranging from companies to universities, patient organizations, and more. Updated regularly and available in six languages, the hub is a key step forward in T2EVOLVE’s strategic objective to involve and guide patients throughout their clinical journey.

Stakeholder involvement is also at the heart of the European Patient Survey on CAR T-cell therapy, a survey developed alongside QUALITOP and in close collaboration with patient advocacy groups, patients, and carers. By further understanding patient experiences, T2EVOLVE can better improve quality of life for patients and carers.

More information is available on the T2EVOLVE website, led by EHA.
EUROPEAN PROJECTS
ABOUT CELLULAR THERAPIES:
GoCART

ADVANCING CELLULAR THERAPIES WITH DIVERSE STAKEHOLDER GROUPS

In 2022, The GoCART Coalition further advanced its vision to create a platform driven by input from a diverse group of stakeholders jointly developing projects to advance cellular therapies in Europe.

Following extensive work by an expert group of coalition pharmacists, a guidance document was developed to harmonize implementation of hospital pharmacy CAR-T services across Europe. A similar guidance document for apheresis also saw a number of developments to prepare it for publication in early 2023.

The coalition also enabled audiences to learn from stakeholders by hosting 10 clinical case discussions and 6 best practice sharing sessions by nurses. The purpose of these sessions was to further maximize the potential of novel cellular therapies.
FINANCIAL REPORT
2022 was a successful year, filled with hybrid conferences, meetings, and both live and digital education. EHA significantly expanded its online education and offered new learning opportunities to the hematology community in Europe and beyond. This progress was made possible by the continuous support of and collaboration with EHA partners. Thanks to your support, we were able to expand our educational offering to 82 courses, 52 podcasts, 15 programs, and 51 clinical cases on the EHA Campus. We also reached more than 10,000 hematologists via different social media with microlearning opportunities such as “Learning Mondays” and “Thinking Thursdays”.

In-person education was also resumed in both live and digital formats. In 2022, EHA launched the Lighting the Flame program to spark interest in hematology among medical students with a series of videos to pique an interest in hematolgy. 90 trainees were able to improve their knowledge by following the EHA Masterclass program online. Lastly, 28 mentees benefited from participating in mentorship programs (TRTH and CRTH) and 29 researchers received the means to take their research further thanks to EHA grants.

EHA expresses its deep gratitude to the EHA Corporate Sponsors for their trust and commitment during the year. Your continuous support helps EHA to fulfill its mission in connecting hematologists worldwide, advocating the interests of hematologists and hematology, supporting career development and research, and harmonizing education in hematology.

EHA is looking forward to continuing our collaboration and strengthening relationships with existing partners, as well as welcoming new organizations to support EHA activities.

Finally, EHA would like to thank supporters of the EHA Friends’ Fund. With your support, the EHA Friends’ Fund helps to build a healthier and more promising future for hematology patients by providing opportunities in education and career development for junior hematologists.
EHA is a common good non-profit organization under Dutch law. It receives its funding through corporate partnerships with industry partners and through activity-based sponsorships for EHA’s programs. Profits generated from its congress and other programs are invested in other activities that serve the hematology community, according to the objectives and mission of EHA. EHA is a Board-led organization. The Executive Board, the Board, and its committee members contribute on a voluntary basis to the association’s work for a defined period. The EHA Executive Office leads all efforts in executing the EHA strategy and employs a variety of highly experienced employees.

**BALANCE SHEET AS OF DECEMBER 31, 2022 (IN €’000)**

<table>
<thead>
<tr>
<th>Assets</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed assets</td>
<td>180</td>
<td>260</td>
</tr>
<tr>
<td>Current assets</td>
<td>1,108</td>
<td>1,957</td>
</tr>
<tr>
<td>Cash and Cash equivalents</td>
<td>26,622</td>
<td>28,637</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>27,910</td>
<td>30,854</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reserves</td>
<td>22,722</td>
<td>25,914</td>
</tr>
<tr>
<td>Current Liabilities</td>
<td>5,188</td>
<td>4,940</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>27,910</td>
<td>30,854</td>
</tr>
</tbody>
</table>
## STATEMENT OF INCOME AND EXPENSES 2022 (IN €’000)

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Income</strong></td>
<td>11,837</td>
<td>21,251</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual Congress</td>
<td>1,746</td>
<td>7,582</td>
</tr>
<tr>
<td>Research and Mentoring</td>
<td>2,354</td>
<td>3,675</td>
</tr>
<tr>
<td>Education and Training</td>
<td>392</td>
<td>850</td>
</tr>
<tr>
<td>Direct operations</td>
<td>124</td>
<td>186</td>
</tr>
<tr>
<td>Indirect operations*</td>
<td>4,095</td>
<td>5,446</td>
</tr>
<tr>
<td>European projects</td>
<td>84</td>
<td>185</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>8,796</td>
<td>17,923</td>
</tr>
<tr>
<td><strong>Operational result</strong></td>
<td>3,041</td>
<td>3,327</td>
</tr>
<tr>
<td><strong>Financial income / (expenses)</strong></td>
<td>(143)</td>
<td>(136)</td>
</tr>
<tr>
<td><strong>Result</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>including staff costs</em></td>
<td>2,898</td>
<td>3,192</td>
</tr>
</tbody>
</table>
Based on EHA’s Strategy, input was collected from EHA’s Committees and Working Groups for the 2023 Work Plan and Budget. Input was provided at two levels:

- EHA’s existing program portfolio and proposed strategic direction in 2023.
- New EHA program initiatives fitting within EHA’s overarching strategy.
- For ongoing projects as well as for new program initiatives, the scopes of these initiatives were developed, including the budgets, and collected in a draft Work Plan and Budget 2023 which was approved by the Board. The budget is summarized in the table below.

### BUDGET 2023 (IN €’000)

<table>
<thead>
<tr>
<th></th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Income</td>
<td>20,658</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Expenses</td>
<td></td>
</tr>
<tr>
<td>Annual Congress</td>
<td>8,374</td>
</tr>
<tr>
<td>Research and Mentoring</td>
<td>4,787</td>
</tr>
<tr>
<td>Education and Training</td>
<td>1,505</td>
</tr>
<tr>
<td>Community</td>
<td>1,010</td>
</tr>
<tr>
<td>European affairs</td>
<td>143</td>
</tr>
<tr>
<td>Communications</td>
<td>430</td>
</tr>
<tr>
<td>Indirect operations*</td>
<td>4,970</td>
</tr>
<tr>
<td>Financial income and expenses</td>
<td>-</td>
</tr>
<tr>
<td>Total expenses</td>
<td>21,619</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Financial income / (expenses)</td>
<td>-</td>
</tr>
<tr>
<td>Budgeted result</td>
<td>(961)</td>
</tr>
</tbody>
</table>
INVESTING IN THE FUTURE
At the November meeting, the EHA Board also discussed its ambition to grow and expand activities in Research & Mentoring, Education, Congress & Meetings, and Communication to ensure that EHA broadens its current benefits for members and nonmembers and can fulfill and broaden its strategic goals. In lieu of this, the EHA Board decided that one additional department should be specifically formed to solely work on relationship building for EHA stakeholders in and beyond Europe. EHA’s financial position is solid, allowing the association to develop and implement considerable programs that contribute to achieving its strategic goals. New programs have been presented to the EHA Board to obtain approval for an additional investment plan for 2023 and beyond.

NOTES TO THE FINANCIAL STATEMENTS
The financial statements are prepared in accordance with guideline RJ640 (Non-profit organizations) of the Dutch Accounting Standards Board. The financial statements are prepared in Euros, the functional currency of the European Hematology Association. Valuation of assets and liabilities and determination of the result takes place under the historical cost convention. Unless presented otherwise at the relevant principle for the specific balance sheet item, assets and liabilities are carried at nominal value. Income and expenses are accounted for on an accrual basis. Profits are only included when realized on the balance sheet date. Losses originating before the end of the financial year are considered if they have become known before preparation of the financial statements. Revenues from goods are recognized upon delivery. The cost price of these goods is allocated to the same period. Revenues from services are recognized in proportion to the services rendered. The cost price of these services is allocated in the same period. Transactions in foreign currencies are recorded at the FX-rates of the dates of the transactions. At the end of the financial year the unsettled balances of foreign currency transactions are revalued at the year-end FX-rates.
“TOWARDS A CURE FOR ALL BLOOD DISORDERS”